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Cardiac arrhythmia is common in cardiac disease, but our understanding of the 
cellular mechanisms underlying arrhythmia is incomplete. Alternans, the beat-to-beat 
alteration in cardiac electrical or mechanical signals, has been linked to susceptibility to 
lethal arrhythmias in human heart failure (HF) as well as in human chronic atrial fibrillation 
(cAF). In addition, early afterdepolarizations (EADs), a type of aberrant cellular behavior 
that causes spontaneous slowing or reversal of normal repolarization, have been implicated 
as an arrhythmogenic trigger in human hypertrophic cardiomyopathy (HCM). Abnormal 
myofilament dynamics has been observed in human HF, HCM, and cAF, but whether this 
aberrant behavior alters the formation of alternans or EADs remains unknown.  
To address this gap in understanding, a computational modeling approach was 
taken. Three mechanistically-based bidirectionally coupled human electromechanical 
myocyte models were constructed, under the conditions of HF, HCM, or cAF. Our goal 
was to elucidate whether aberrant myofilament dynamics modulate the cellular drivers of 
arrhythmogenesis in human cardiac disease. In simulations with our human HF ventricular 
myocyte model, we found that the magnitudes of force, calcium, and action potential 
voltage alternans were modulated by heart failure induced-remodeling of mechanical 
parameters and sarcomere length due to the presence of myofilament feedback (MEF) at 
clinically-relevant pacing rates. In simulations with our human HCM ventricular myocyte 
model, we found that incorporating MEF diminished the degree of repolarization reserve 
reduction necessary for EADs to emerge and increased the frequency of EAD occurrence, 
especially at faster pacing rates. Longer sarcomere lengths and HCM-induced enhanced 
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thin filament activation diminished the effects of MEF on EADs. Finally, in simulations 
with our human cAF atrial myocyte model, we found that MEF, via cooperativity in 
Troponin C buffering of cytoplasmic Ca2+, diminished the magnitude of action potential 
duration alternans. Also, enhanced thin filament activation, via either cAF-induced 
myofilament remodeling or longer sarcomere lengths, enhanced action potential duration 
alternans.  
Together, this thesis provides evidence that myofilament protein dynamics 
mechanisms play an important role in EAD and alternans formation, suggesting that 
targeting MEF or reversing disease induced myofilament remodeling may be alternative 
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1.1 Organization and Summary of the Thesis 
The organization of this thesis, which investigates the myofilament dynamics 
mechanisms that modulate cellular drivers of arrhythmogenesis in human cardiac disease, 
is as follows: 
Chapter 2 presents a brief background of cardiac electrophysiology and 
electromechanics, which are crucial for understanding the research presented in this thesis. 
In addition, general information regarding arrhythmogenesis in cardiac disease and its 
cellular drivers is also included. Information regarding arrhythmogenesis and its cellular 
mechanisms in human heart failure (HF), hypertrophic cardiomyopathy (HCM), and atrial 
fibrillation (AF) are discussed in Section 1 of Chapters 4, 5, and 6 respectively. 
In Chapter 3, we explain our rationale for using computational modeling 
approaches to understand the mechanisms underlying the cellular drivers of 
arrhythmogenesis. Additionally, general approaches for modeling the human 
cardiomyocyte are discussed.  
Chapter 4 describes our methodology to build a mechanistically-based 
electromechanical model of the human ventricular myocyte and to incorporate HF-induced 
ionic and myofilament remodeling. We used this model to study the mechanisms linking 
force alternans to action potential voltage alternans (a known cellular driver of 
arrhythmogenesis) in the human failing myocyte, with emphasis on those acting at the 
clinically-relevant pacing rates of <110 bpm.  
In Chapter 5, we explored whether myofilament protein dynamics mechanisms 
modulate EAD formation (another type of cellular driver of arrhythmogenesis) in human 
HCM for varying degrees of reduced repolarization reserve, and to uncover how these 
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mechanisms are affected by pacing rate, sarcomere length, and the degree of HCM-induced 
myofilament remodeling. This investigation utilized our previously developed model of 
the human ventricular myocyte (described in Chapter 4), which we modified to incorporate 
HCM-induced ionic and myofilament remodeling.  
In Chapter 6, we developed a biophysically-accurate electromechanical model of 
the human atrial myocyte and incorporated AF-induced ionic and myofilament remodeling. 
Using this model, we investigated whether remodeling of myofilament protein dynamics 
mechanisms modulate action potential duration alternans (also a cellular driver of 
arrhythmogenesis) in cAF. We also aimed to uncover how these mechanisms are affected 
by sarcomere length and the degree of AF-induced myofilament remodeling.  
Finally, Chapter 7 concludes this thesis by discussing the significance of the results 









Chapter 2 Background: 





2.1 Blood Flow and the Healthy Human Heart 
The purpose of the heart is to pump blood throughout the body to bring oxygen and 
essential nutrients to cells and to remove carbon dioxide and waste products from them. 
The human heart consists of 4 chambers: the right atrium, the left atrium, the right ventricle, 
and the left ventricle as shown in Figure 2.1. In healthy hearts, deoxygenated blood is 
carried to the right atrium from the inferior and superior vena cavae, which receive blood 
from the other veins in the systemic 
circulatory system. This deoxygenated 
blood passes through the tricuspid (right 
atrioventricular) valve into the right 
ventricle, where it is propelled past the 
pulmonary valve into the pulmonary 
arteries due to the coordinated 
contraction of the cardiac cells 
(cardiomyocytes) in the right ventricle. 
From the pulmonary arteries, the blood 
moves via the arterioles into the pulmonary capillary bed where carbon dioxide in the blood 
is exchanged for oxygen contained in the alveoli of the lungs. The newly oxygenated blood 
returns to the heart via the pulmonary venules and veins. After entering the left atrium, it 
passes through the mitral valve into the left ventricle where is it propelled past the aortic 
valve and into the aorta due to contraction of the left ventricle. The oxygenated blood then 
moves through the arteries and arterioles of the systemic circulatory system until it reaches 
the systemic capillary bed. Oxygen is delivered to the cells and carbon dioxide moves from 
Figure 2.1 Cardiac Blood Flow 
 




the cells into the blood. The now deoxygenated blood returns via the venules to the veins 
and ultimately the right atrium.  
 
2.2 Electrophysiology and Electromechanics of the 
Healthy Human Heart 
2.2.1 Normal Cardiac Rhythm 
Proper blood flow 
in the human body relies on 
ability of the heart’s four 
chambers to work as a 
synchronized unit, thus 
contracting and pumping 
blood in a coordinated 
manner. To facilitate this 
coordinated contraction, 
timed electrical signals 
propagate in a regularly timed manner along a specialized conduction pathway as shown 
in Figure 2.2.1. In the healthy human heart, the signals are initiated by specialized 
pacemaker cells in the sinoatrial node, located at the roof of the right atrium. These 
electrical signals propagate through the cardiomyocytes in right and left atrium via 
intracellular gap junctions until they arrive at the atrioventricular node, located at the floor 
of the right atrium between the atria and ventricles. The conduction of the signals slows in 
Figure 2.2.1 Cardiac Conduction System 
 





the atrioventricular node to ensure completion of contraction in the atria and to provide 
sufficient time for the ventricles to fill with blood. The electrical impulses then propagate 
to the bundle of His, which allows them to cross the fibrous tissue separating the atria and 
ventricles and arrive at the Purkinje fibers. From there, the electrical signals travel down 
the fast conducting Purkinje fibers until they reach and activate the working ventricular 
cardiomyocytes. This precisely orchestrated electrical signaling system allows the 
mechanical contraction of the chambers to occur synchronously, allowing the heart to 
efficiently pump blood throughout the body. 
 
2.2.2 Cardiac Action Potential  
The electrical signals produced and propagated throughout the cells of the heart are 
called action potentials (APs). An AP is characterized by the depolarization and 
repolarization of the excitable, semipermeable cell membrane (called the sarcolemma). The 
voltage across the sarcolemma is called the transmembrane potential (Vm) and is changed 
over time as ions flow into and out of the cardiomyocyte due to ion channels, transporters, 
and exchangers. When Vm is negative (positive), there is a net negative (positive) charge 
inside the cell relative to the extracellular space which is located outside the cell beyond 
the sarcolemma boundary. Although the AP is unique for each type of cardiomyocyte, there 
are two main types of APs, that experienced by the pacemaker cells in the sinoatrial node, 
and that experienced by the working cardiomyocytes such as ventricular and atrial cells. 
Since the work in this thesis pertains to atrial and ventricular cells, this background will 
focus on the APs of those cells.  
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There are five distinct phases in 
the AP of working cardiomyocytes as 
shown in Figure 2.2.2. In the first phase, 
called phase 4 or the resting phase, the 
cardiomyocyte has a resting Vm of 
approximately -80 mV, which occurs 
due to the electrochemical balance of 
ions, predominantly sodium, calcium, 
and potassium. In this phase, the 
sodium-calcium exchanger (INaCa), the 
sodium-potassium pump (INaK), and the 
inward rectifying potassium current (IK1) are active, although IK1 is dominant. As a result, 
the Vm during phase 4 is close to the reversal potential for potassium (-90 mV). When the 
second phase (called phase 0) occurs, the sodium channel (INa) opens, allowing positively 
charged sodium ions (Na+) to enter the cell, resulting in a positive inward current that raises 
Vm toward the Nerst potential for sodium (55 mV). When INa inactivates, transiently 
activated potassium channels open (Ito) briefly allowing positively charged potassium ions 
(K+) to exit the cell, causing a short period of repolarization (phase 1). In phase 2, L-type 
calcium channels (ICaL) open, allowing positively charged calcium ions (Ca2+) to enter the 
cell. In addition, INaCa and INaK operate in the inward direction (produce positive inward 
current), and the slow delayed outward potassium current (IKs) begins to activate, allowing 
potassium ions to leave the cell. Together the balance of these ion currents, cause the 
“plateau” of Vm in the AP. In the final phase (phase 3), the outward rapid rectifier 
Figure 2.2.2 Cardiac Action Potential 
 




potassium current (IKr) and IK1 open, while IKs continues to be open, and ICaL inactivates. 
This causes a swift depolarization of Vm. Once Vm depolarizes back to its resting value (-
80 mV), the cardiomyocyte has returned back to phase 4. Although atrial and ventricular 
cells both go through the five distinct AP phases described above, there are slight 
differences. However, the primary difference is that the plateau in Vm in phase 2 is shorter 
in atrial cells than in ventricular cells. 
 
2.2.3 Excitation-Contraction Coupling  
The process by which electrical APs generate contractile force in cardiomyocytes 
is called excitation-contraction coupling (shown in Figure 2.2.3.1) and occurs due to the 
interaction of free intracellular Ca2+ ions with myofilament protein complexes. As 
described in the 
preceding section, 
during phase 2 of the 
AP, Ca2+ ions pass 
through the 
sarcolemma via ICaL 
and enter a region of 
the cell next to the 
sarcolemma that is also 
adjacent to the 
sarcoplasmic reticulum 
(SR) and contains 
Figure 2.2.3.1 Excitation Contraction Coupling 
 




ryanodine receptors. There are a variety of names given to this region, including dyadic 
space, subspace, junctional space, and cleft. The Ca2+ ions bind to the ryanodine receptors 
in this region, causing a conformational change that allows a rapid release of large amounts 
of Ca2+ ions stored in the SR (Irel). This positive feedback process is termed ‘calcium 
induced calcium release’. When the Ca2+ ions are release from the SR and enter the cleft, 
they diffuse into the intracellular space, where the concentration of Ca2+ ions is termed 
[Ca]i. These free Ca2+ ions in the intracellular space can bind to Troponin C or to other 
Ca2+ buffers like calmodulin. When Ca2+ binds to Troponin C, a conformation change 
occurs in Troponin I, causing tropomyosin to leaves its groove on the actin filament. This 
removes the inhibitory effect of Troponin I, making it possible for myosin heads to bind to 
actin, and thus making crossbridge (XB) formation and cycling permissible.  
 
 
Figure 2.3.2.2 Crossbridge Cycling 
 
This figure was provided by http://droualb.faculty.mjc.edu  
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In the first step of XB cycling, the myosin head, which is already attached to an 
ADP-Pi, weakly binds to the now available actin binding site as shown in Figure 2.3.2.2. 
This is considered a weakly bound crossbridge, since the myosin head forms a bridge 
between the thin myofilament (actin) and the thick myofilament (myosin) that is weak in 
strength. Then Pi is released from the complex, causing the myosin head to be strongly 
bound to the actin site. Next, the myosin head undergoes a conformational rotation, 
resulting in active force generation. This step is often called the “power stroke.” ADP is 
then released from the myosin head, allowing it to dissociate from the actin filament and 
bind preferentially to ATP. The ATP is then hydrolyzed by the myosin ATPase, resulting 
again in a myosin-ADP-Pi configuration. This cycle of crossbridge formation can occur at 
all of the other sites along the actin filament where myosin heads are nearby, provided that 
the actin site has been made available by Ca2+ binding to Troponin C. The cumulative 
active force generation produced by crossbridge cycling allows the sarcomere, the smallest 
structural unit of a cardiac muscle fiber, to shorten. Shortening of the thousands of 
sarcomeres that make up a single cardiomyocyte, leads to contraction of the myocyte. 
Once phase 3 of the AP begins, ICaL closes and Ca2+ ions are no longer being 
released from the SR. The free Ca2+ ions in the intracellular space are pumped back into 
the SR by an ATPase calcium pump (SERCA2a; current is referred to as Iup), or moved 
from the intracellular to extracellular space by INaCa or the sarcolemmal calcium pump 
(ICa,P). The Ca2+ ions that enter the SR are then bound to the calcium binding protein 
calsequestrin, to keep the calcium concentration gradient low, allowing more Ca2+ ions to 
enter the SR. Since the calcium influx into the intracellular space has abated, the above-
mentioned processes become dominant and [Ca]i begins to diminish. Since Ca2+ unbinds 
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from Troponin C once the myosin head dissociates from the actin head and since [Ca]i is 
becoming progressively smaller during phase 3, fewer and fewer Ca2+ ions bind to 
Troponin C, causing more and more actin sites to become unavailable to myosin heads. 
Thus, as [Ca]i decreases, active force generation diminishes and sarcomeres begin to relax 
and return to their resting length. Once the next AP begins, the calcium cycle repeats and 
the cycle of muscle contraction and relation occurs again. 
 
2.2.4 Mechanoelectric Feedback 
While excitation-contraction coupling refers to the process by which electrical 
activation leads to mechanical contraction, mechanoelectric feedback (MEF) is the process 
by which mechanical activity alters electrical activity. MEF occurs at both the organ scale 
and the cellular scale. Details on MEF occurring at the organ scale can be found in this 
review by Pfeiffer et al (Pfeiffer et al., 2014). However, since the work in this thesis focuses 
on the mechanisms underlying the cellular drivers of arrhythmogenesis, this background 
will focus on MEF that occurs at the cellular scale. One mechanism of MEF at the cellular 
scale is stretch-activated currents. These ionic currents are mechanosensitive, meaning that 
the opening of the channels is modulated by cell stretch. A second mechanism of MEF is 
cell to cell coupling via gap junctions at intercalated disks, which occur at the intersection 
of two cells. Mechanical loading can increase the expression of gap junction proteins, 
which can lead to increased conduction velocity, thus altering electrical activity (Gopalan 
et al., 2003; Zhuang et al., 2000). A final mechanism of MEF is myofilament calcium 
sensitivity and cooperativity. It is well known that there is a steeply nonlinear relationship 
between force and calcium in cardiomyocytes and that the amount of force generated is 
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highly dependent on the amount of calcium present and on sarcomere length. The nonlinear 
relationship between calcium and active force generation is believed to occur because 
strongly bound crossbridges can shift tropomyosin into a more favorable location on the 
thin filament, dramatically enhancing the binding affinity of nearby myosin heads to actin 
sites. This enhanced Ca2+-Troponin C binding affinity is also modulated by sarcomere 
length. Thus, if sarcomere length is altered due to a mechanical perturbation, myofilament 
calcium sensitivity and cooperativity are both modulated. This would change the 
availability of calcium in the intracellular space, thus altering calcium handling in the 
cardiomyocyte and the progression of the AP. It is this final mechanism of MEF, 
myofilament calcium sensitivity and cooperativity, that will be investigated in this thesis. 
 
2.3 Electrophysiology and Electromechanics of the 
Diseased Human Heart 
Cardiac disease is a common problem in Americans and others worldwide. While 
cardiac disease can take many forms, the work in this thesis will focus on the following 
three: HF (Chapter 4), HCM (Chapter 5), and AF (Chapter 6). Although details of each 
are described in the first section of their respective chapters, these cardiac diseases share 
several important features. First, the cardiomyocytes in the hearts of patients with these 
diseases have been shown to have electrical and mechanical remodeling (also referred to 
as ionic and myofilament remodeling). Additionally, patients with HF and HCM have an 
increased susceptibility to lethal ventricular arrhythmia, while AF is a type of chaotic 





A cardiac arrhythmia is defined as a condition in which the regular pattern of 
electrical propagation is deranged. Arrhythmias can occur when the heart is beating too 
quickly (tachyarrhythmias) or too slowly (bradyarrhythmias). They can be caused by 
altered electrical impulse formation or conduction.  
Abnormal electrical impulse formation can occur due to a disruption in 
parasympathetic or sympathetic activity, abnormal automaticity (such as ectopic foci), or 
triggered activity. Triggered activity can be caused by early afterdepolarizations (EADs) 
or delayed afterdepolarizations (DADs). EADs, which are a focus of Chapter 5, are 
discussed in more detail in Section 2.3.3 below.  
Irregular electrical impulse conduction includes slow conduction, conduction 
block, and reentry. Reentry occurs when an electrical wave encounters an area of 
conduction block, is able to propagate around the area of block, and always encounters 
excitable tissue in the direction of propagation, including when it reaches previously 
refractory tissue. Therefore, the distance traveled by the electrical wave during one 
refractory period (wavelength) must always be shorter than the length of the reentrant 
circuit. Reduced electrical conduction and shortened APD can both diminish the 
wavelength and thus promote reentry. Reentry can be either anatomical or functional. 
Anatomical reentry occurs when there is a physical, non-conducting area of block, such as 
scar, that the electrical wave must propagate around. Functional reentry occurs when the 
electrical wave propagates around a small unexcited (though excitable) region of tissue. 
This can occur due to spatial heterogeneity in excitability or refractoriness. Action potential 
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duration (APD) alternans and action potential voltage (APV) alternans have both been 
shown to increase spatial dispersion of repolarization across the myocardium, leading to 
unidirectional conduction block and reentry. APD alternans, which are the focus of 
Chapter 6, and APV alternans, the focus of Chapter 4, are both described in more detail in 
Section 2.3.2 below.     
   
2.3.2 Cardiac Alternans 
Alternans is defined as the beat-to-beat alteration in cardiac electrical or mechanical 
signals and can occur at the tissue level or at the cellular level. Types of tissue level 
alternans that have been observed in humans and that have been linked to susceptibility to 
lethal arrhythmias include T-wave alternans and pressure alternans. T-wave alternans 
occurs when there is beat-to-beat variation in the amplitude of the T-wave of an 
electrocardiogram (ECG). Studies have shown that small amplitude T-wave alternans 
(microvolt T-wave alternans; MTWA) is driven by APV alternans in human heart failure 
(Bayer et al., 2010; Narayan et al., 2008), which occurs on the cellular level when the Vm 
amplitude during phases 2 and 3 of the AP oscillates from beat to beat. APV alternans is 
driven by alternans in intracellular calcium transient amplitude, which in turn occurs due 
to altered SR calcium uptake or release (Bayer et al., 2010). Pressure alternans are defined 
as the beat-to-beat oscillation of the amplitude of systolic pressure and can be measured 
noninvasively with an infrared finger photoplethysmograph. At the cellular level, pressure 
alternans are thought to arise from force alternans, defined as the beat-to-beat oscillations 
in the strength of active force production in cardiomyocytes. The molecular mechanisms 
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underlying APV alternans and whether it is linked to force alternans is further investigated 
in Chapter 4.  
Another type of cellular level alternans is APD alternans, defined as the beat-to-
beat oscillation in APD, which has been shown to be an important clinical marker for AF 
risk (Narayan et al., 2002). APD alternans have been shown to be driven by calcium 
transient alternans due to altered ryanodine receptor (RyR) kinetics and down regulation 
of the ICaL. Although the ionic mechanisms of APD alternans have been investigated, little 
is known about the effects of myofilament protein dynamics on APD-ALT in human AF, 
which we investigate in Chapter 6. 
 
2.3.3 Afterdepolarizations 
EADs are a type of aberrant cellular behavior that cause spontaneous (yet triggered) 
slowing or reversal of normal repolarization. EADs occur during late phase 2 or phase 3 of 
a cardiac AP and can lead to several rapid APs or a prolonged series of APs. In contrast, 
DADs occur in late phase 3 or early phases 4 of an AP. Since we investigate the mechanistic 
basis of EADs in human HCM in Chapter 5, we will focus on EADs in this background 
section. EADs occur more commonly when APD is increased and require reduced 
repolarization reserve to be present. Reduced repolarization reserve can result from a 
decreased outward current, an increased inward current, or a combination of both. Due to 
these compromised circumstances, a current that progressively increases as Vm depolarizes 
can potentially overcome and reverse repolarization. ICaL and INaCa both fit this positive 
feedback criterion and are the major currents normally implicated in EAD formation. If 
17 
 
activity of any of the potassium rectifying channels is diminished, APD lengthens and EAD 












3.1 Rationale for Computational Modeling of Cardiac 
Myocytes 
Computational modeling of cardiac myocytes is the use of computer algorithms and 
tools to unveil mechanisms underlying sub-cellular cardiac phenomena to enhance our 
understanding of cardiac disease and potentially aid in the development of improved 
therapeutic approaches. Computational modeling was used for all aspects of the work in 
this thesis.   
Computational modeling was used in this thesis because it has several advantages 
over traditional (“wet lab”) experimental approaches. First, using computer simulations 
allows the scientist to make predictions regarding complex phenomena that are too difficult 
or significantly more difficult to study experimentally. Second, computational modeling 
can illuminate the significance of individual parameters in a particular system, which may 
difficult or impossible to isolate using traditional approaches. Third, computational 
modeling allows the scientist to study a system hypothetically, which is often cheaper and 
faster than studying the system experimentally. This can help aid in the design of traditional 
experiments that can then be used to confirm the computational findings. 
 
3.2 Modeling Cell Membrane Kinetics 
The first mathematical model of an excitable cell membrane was published in 1952 
by Hodgkin and Huxley in a seminal paper titled “A quantitative description of membrane 
current and its application to conduction and excitation in nerve” (Hodgkin and Huxley, 
1952). Their model of the squid giant axon membrane was able to accurately reproduce the 
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experimentally measured AP for the first time. In 1962, Denis Noble built upon the work 
of Hodgkin and Huxley and published the first model of a cardiac AP (Noble, 1962). The 
basic tenets are as follows. The total membrane current is divided into capacitive and ionic 
components as shown in Equation 3.2 below: 
 
𝐼𝑚 =  𝐶𝑚
𝑑𝑉𝑚
𝑑𝑡
+  𝐼𝑖𝑜𝑛 + 𝐼𝑡𝑟𝑎𝑛𝑠 
(Equation 3.2) 
 
where Im is the total membrane current density, Cm is the membrane capacitance per unit 
area, Vm is the transmembrane potential, Iion is the ionic current density, and Itrans is the 
current density of a transmembrane stimulus. In the Hodgkin and Huxley formulation, Iion 
is comprised of the summation of INa, IKr, and a background leak current (Il). The ionic 
conductances of INa and IKr depend on gating variables that have opening and closing rates 
dependent on Vm. These current equations were derived by fitting mathematical equations 
to the experimental measurements Hodgkin and Huxley obtained from voltage clamp 
experiments. Today, we know there are many more currents involved in the cardiac AP, as 
described in Section 2.2.2 above. Modern ionic models incorporate these currents in their 
formulation of Iion. In addition, modern ionic models incorporate key features that enable 
them to model different animal species (including humans), as well as different cell types 
(such as atrial and ventricular cells). The ionic models used in the three studies in this thesis 




3.3 Modeling Calcium Handling 
Modern ionic models differ slightly in how they represent the flow of Ca2+ ions in 
and out of the cell. Generally, Ca2+ ions enter the cell’s diadic space via ICaL and then 
diffuse into the intracellular space, where they are eventually pumped back into the SR via 
Iup or back out of the cell via INaCa and ICa,P. Cardiac ionic models generally represent these 
regions (diadic, intracellular, SR) as separate lumped compartments within the cell, each 
with its own distinct Ca2+ concentration and its own distribution of ionic currents. Some 
older models do not include the representation of the diadic space. Some newer models 
also include a space called the sub-sarcolemma that lies adjacent to the sarcolemma on the 
interior of the cell but is distinct from the diadic cleft. The ionic models in Chapters 4 and 
5 does not contain a sub-sarcolemmal space, while the model in Chapter 6 does. In 
addition, some models sub-divide the SR into junctional and network components. Simple 
diffusion of Ca2+ ions occurs between the compartments that are not separated by 
membranes, such as the SR.  
 
3.4 Modeling Cardiac Myofilament Dynamics  
Cardiac myofilament models are designed to quantitatively capture the interaction 
between the active and myosin filaments, and calcium based activation of them. The 
earliest known crossbridge cycling model was developed by Huxley (Huxley, 1957) in 
1957. It consisted of only two states for the XB, attached and detached, and the rate 
constants were only dependent on the relative positions of the actin binding site and the 
equilibrium position of the closest XB. Models range from the 2 XB states found in the 
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Huxley model to 7 XB states in a model developed by Pate and Cooke (Pate and Cooke, 
1986). Although models with more states are able to more accurately represent 
experimentally observed biochemical XB states, they are computationally expensive. 
Therefore, modern myofilament models aim to balance biophysical accuracy with 
computational efficiency. The Rice et al model (Rice et al., 2008) was chosen for the work 
in this thesis since it optimized the balance of accuracy and efficiency. In addition, the Rice 
et al model incorporates important calcium-based activation and sarcomere length-based 
sensitivity mechanisms. An extensive review of this topic can be found in Trayanova and 









Chapter 4 Study 1: 
Rate-dependent force, intracellular 
calcium, and action potential voltage 
alternans are modulated by sarcomere 
length and heart failure induced-
remodeling of thin filament regulation 





This study has been published in Progress in Biophysics and Molecular Biology (Zile and 
Trayanova, 2016) and reprinted with permission from Elsevier publishing. 
 
4.1 Introduction 
Ventricular arrhythmias are the most common cause of sudden cardiac death, 
resulting in > 300,000 US deaths annually (Lloyd-Jones et al., 2009). The standard 
procedure for preventing sudden cardiac death is to implant a cardioverter defibrillator 
(ICD), which delivers a strong electric shock to terminate arrhythmias. Since current 
methods for identifying patients who require ICDs have only been partially successful 
(Bardy et al., 2005), there is a need for noninvasive predictors with high sensitivity and 
specificity. Indeed, robust methods for stratifying the risk of lethal cardiac arrhythmias 
would decrease morbidity and mortality in patients with cardiovascular disease and reduce 
health care costs (Goldberger et al., 2011). Approaches for stratifying risk of cardiac 
arrhythmias involve testing for abnormalities in the ECG, then using the results to identify 
patients who would benefit from ICD therapy. ECG-based risk stratification methods scan 
for abnormalities in ventricular depolarization (late potentials (Kuchar et al., 1987),  
fractionated QRS complexes (Das et al., 2006)) and repolarization (T-wave alternans 
(Rosenbaum et al., 1994), and QT variability, dispersion, and instability (Berger et al., 
1997; Chen et al., 2011; Chen et al., 2013; Chen and Trayanova, 2012; Couderc et al., 
2007)). However, the mechanisms underlying these ECG indices, and their relationship to 
lethal cardiac arrhythmias, are not fully understood. This lack of knowledge likely explains 
why results of clinical trials to correlate surface EGG indices to lethal cardiac arrhythmias 
are often contradictory (Goldberger et al., 2011).  
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Of the above ECG indices, T-wave alternans have received possibly the most 
attention. Research has reported a strong correlation between increased arrhythmia risk and 
the presence of T-wave alternans (Narayan, 2006; Qu et al., 2010), defined as the beat-to-
beat alternation of the timing or shape of the repolarization wave of the ECG. In the clinical 
setting, testing for Microvolt T-wave Alternans (MTWA) has been found to be a risk 
marker for lethal ventricular arrhythmias and sudden cardiac death (Cutler and Rosenbaum, 
2009), to have high negative predictive power (Narayan, 2006) and to be particularly 
promising in dichotomizing patients that would and would not benefit from ICD therapy 
(Bloomfield et al., 2006; Hohnloser et al., 2009). However, the mechanistic basis of 
MTWA preceding lethal ventricular arrhythmias has long been under debate. Until the last 
decade, it was believed that a steep action potential duration (APD) restitution (>1) at rapid 
heart rates (Weiss et al., 2006) produces alternans in APD that underlie T-wave alternans 
and the genesis of fibrillation (Pastore et al., 1999). However, MTWA is most successful 
in stratifying risk in patients at near-resting heart rates <110 bpm, where APD restitution 
is flat (Narayan et al., 2007). Computational models of the LV wall in combination with 
clinical data revealed that abnormal handing of intracellular calcium underlies alternans in 
action potential voltage (APV-ALT), defined as the oscillation of the plateau voltage of the 
action potential, which results in MTWA at moderate heart rates, i.e. <110 bpm (Bayer et 
al., 2010; Narayan et al., 2008). Thus APV-ALT is the cell-level driver of MTWA at these 
rates under the conditions of heart failure. 
Alternatively, noninvasively measured pressure alternans, defined as the beat-to-
beat oscillation of the amplitude of systolic pressure, has been found to be a predictor of 
worsening heart failure and increased cardiac mortality (Hirashiki et al., 2010; Hirashiki et 
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al., 2006; Ito et al., 2012; Kashimura et al., 2014; Kim et al., 2014; Selvaraj et al., 2011). 
Pressure alternans also occurs simultaneously with MTWA in patients at near resting heart 
rates, thus indicating that pressure alternans, which have higher signal-to-noise ratio 
(Selvaraj et al., 2011), may be a better predictor of the propensity for ventricular 
arrhythmias and sudden cardiac death, however the mechanisms remain unknown.  
At the cellular level, pressure alternans arise from force alternans (FORCE-ALT), 
defined as the beat-to-beat oscillations in the strength of active force production in cardiac 
muscle. APV-ALT at heart rates <110 bpm has been found to be driven by beat-to-beat 
fluctuations in the amplitude of the intracellular calcium concentration (CA-ALT) (Bayer 
et al., 2010; Narayan et al., 2008). CA-ALT has also been shown to underlie force alternans 
(FORCE-ALT), in animal experiments with cardiac muscle preparations (Kihara and 
Morgan, 1991; Kotsanas et al., 1996; Lab and Lee, 1990; Orchard et al., 1991) and perfused 
hearts (Brooks et al., 1994; Lee et al., 1988), but only at fast pacing rates. Clearly, to date, 
no studies have investigated FORCE-ALT in human myocytes at rates <110 bpm, and 
although calcium dysregulation is a likely candidate, the exact mechanistic link between 
APV-ALT and FORCE-ALT in the failing human myocyte at the clinically important near-
resting heart rates remains unknown. Therefore, our goal was to investigate the 
mechanisms linking FORCE-ALT to APV-ALT in the human failing myocyte, with 
emphasis on those acting at the clinically-relevant pacing rates of <110 bpm, and to 
uncover how the link between FORCE-ALT and APV-ALT is affected by various 





4.2.1 Human Electromechanical Myocyte Model 
To uncover the mechanism linking FORCE-ALT to APV-ALT, a mechanistically-
based human electromechanical myocyte model was used. The electromechanical model 
combined the human endocardial ventricular membrane kinetics model by ten Tusscher et 
al (ten Tusscher and Panfilov, 2006) and the myofilament dynamics model by Rice et al 
(Rice et al., 2008). The 2006 ten Tusscher et al formulation was used because it 
incorporated an extensive description of intracellular calcium handling, which was found 
to be critical in the development of APV-ALT in previous studies of human heart failure 
(Bayer et al., 2010; Narayan et al., 2008). The Rice et al model, which describes the 
activation of the thin filament by intracellular calcium binding to Troponin C as well as 
thin filament binding to thick filament crossbridges (XBs) using a 5 state Markov model, 
was chosen because it was computationally efficient while incorporating important 
biophysical detail and cooperativity mechanisms. Since the Rice et al myofilament model 
was developed based on rabbit data we adjusted it to match human force data. This was 
done by modifying XB cycling and calcium-based thin filament activation parameters 
following the approach in de Oliveira et al (de Oliveira et al., 2013). To account for the 
differences between the ionic model used by de Oliveira et al (the 2004 formulation of the 
ten Tusscher et al model (ten Tusscher et al., 2004)) and by us (ten Tusscher and Panfilov, 
2006), additional modifications to calcium-based thin filament activation were made. 
Specifically, we decreased thin filament activation by reducing kon, a parameter regulating 
the binding affinity of Ca to high and low regulatory sites on Troponin C, to 95% of the 
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baseline value used in Rice et al, in order to increase the time to peak force value so that it 
fell in the physiological range of human values (Mulieri et al., 1992; Pieske et al., 1996). 
The ionic and myofilament models were strongly coupled by incorporating 
myofilament feedback on calcium dynamics (Figure 4.1); this was done by incorporating 
a dynamic term for troponin buffering of intracellular calcium ([Ca]Troponin) using the 
approach in Rice et al. Strongly coupling the models with a dynamic representation of 
[Ca]Troponin was important and necessary, because it has been shown to be crucial for 
accurately reproducing contractile experiment data in myocyte simulations (Ji et al., 2015). 
This [Ca]Troponin term represents the amount of calcium bound to troponin and incorporates 
the cooperativity of calcium-troponin binding due to strongly bound nearby XBs. However, 
in the 2006 ten Tusscher and Panfilov model, troponin buffering of calcium is combined 
with calmodulin buffering of calcium and is represented using a steady state 
approximation. Therefore, to incorporate feedback from the myofilament model to the 
ionic model, we separated the combined buffering term in ten Tusscher and Panfilov into 
two terms. The [Ca]Troponin term from Rice et al, calculated using ordinary differential 
equations, was used for troponin buffering of calcium, and a steady state approximation 
was used for calmodulin buffering of calcium ([Ca]Calmodulin) using the same approach as 
de Oliveira et al. The following equation from de Oliveira et al was used to update the 
intracellular calcium concentration in the ionic model, using the [Ca]Troponin term calculated 
by the myofilament model, at each time step: 
 
 [𝐶𝑎]𝑇𝑜𝑡𝑎𝑙 =  [𝐶𝑎]𝑖 + [𝐶𝑎]𝐶𝑎𝑙𝑚𝑜𝑑𝑢𝑙𝑖𝑛 + [𝐶𝑎]𝑇𝑟𝑜𝑝𝑜𝑛𝑖𝑛              
 




where [Ca]Total is the total calcium in the cytoplasm, [Ca]i is the free calcium in the 
cytoplasm, [Ca]Calmodulin is the total calcium buffered by calmodulin in the cytoplasm, and 
[Ca]Troponin is the total calcium bound to Troponin C.  
 
 
Figure 4.1 Strongly Coupled Human Electromechanical Myocyte Model with 
myofilament feedback via [Ca]Troponin. A modified version of the Markov state diagram of 
the myofilament model from Rice et al, which describes the activation of the thin filament 
by intracellular calcium binding to Troponin C as well as thin filament binding to thick 
filament crossbridges (XBs), is shown. The transition rates (knpT and kpnT) between the thin 
filament states where XB formation is inhibited (NXB) and where weakly bound XB 
formation is possible (PXB) are both functions of perm50, kon, koffH, and koffL. The rate knpT 
is also dependent on kn_p, and kpnT is additionally dependent on kp_n. The XBPreR and XBPostR 
states represent a thin filament with a strongly bound XB that do not and do, respectively, 
have rotated myosin heads which induced strain (Rice et al., 2008).  
 
A weakly coupled version of the model (with no feedback) was created by 
removing the [Ca]Troponin term from Equation 4.1. Its sole purpose was to aid in examining 
how myofilament feedback affected the development of alternans.  
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The model did not incorporate stretch-activated channels since there is no 
experimental evidence that heart-failure induced APV-ALT at low heart rates would be 
affected by a potential opening of the channel.  
 
4.2.2 Incorporating Heart Failure Remodeling 
We simulated human heart failure in our electromechanical model by incorporating 
electrical and mechanical remodeling. Electrical remodeling was represented by abnormal 
calcium handing. Specifically, we reduced the sarcoplasmic reticulum calcium uptake 
current (Iup) to 27% of its baseline value in the ten Tusscher et al model (Table 4.1), similar 
to Narayan et al (Narayan et al., 2008) and Bayer et al (Bayer et al., 2010), to represent 
reduced SERCA2a expression (Hasenfuss et al., 1994) and increased dephosphorylated 
phospholamban (Schmidt et al., 1999) observed in human heart failure. This specific 
feature of heart failure remodeling was incorporated because it has been shown to be crucial 
to the development of APV-ALT in previous studies of human heart failure (Bayer et al., 
2010; Narayan et al., 2008). 
Mechanical remodeling was incorporated to simulate altered thin filament 
activation and XB cycling rates found in human heart failure. Changes in thin filament 
activation have been linked to altered phosphorylation of cardiac Troponin I (cTnI) 
(Messer et al., 2007), which has been shown to be decreased by up to 87% (Messer et al., 
2007; Zaremba et al., 2007). Alterations in XB cycling rates have been linked to changes 
in phosphorylation of myosin light chain 2 (MLC-2) (Levine et al., 1996; Moss and 
Fitzsimons, 2006; Olsson et al., 2004; Patel et al., 1998) and cardiac myosin-binding 
protein C (cMyBP-C) (Coulton and Stelzer, 2012; Flashman et al., 2004). Studies have 
found that phosphorylation of the two isoforms of MLC-2 is unchanged (van der Velden 
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et al., 2003a) or reduced by 34%-69% (van Der Velden et al., 2001; van der Velden et al., 
2003a; van der Velden et al., 2003b; Zaremba et al., 2007). Additionally, cMyBP-C has 
been shown to be decreased by at least 50% (El-Armouche et al., 2007; Zaremba et al., 
2007). Furthermore, myocardial Ca2+ sensitivity, which incorporates the combination of 
the effects of thin filament activation and XB cycling rates on force production, has been 
shown to be altered in human heart failure. In studies, myocardial Ca2+ sensitivity has been 
found to increase by 2-6% in human heart failure (van der Velden et al., 2000; van der 
Velden et al., 2006; Wolff et al., 1996) and by 1-2% in animal models of heart failure (de 
Waard et al., 2007; Lamberts et al., 2007; Wolff et al., 1995), not change in human heart 
failure (Ambardekar et al., 2011), and decrease by 2-3% in animal models of heart failure 
(Belin et al., 2007; Belin et al., 2006).  
Despite the uncertainty regarding the exact amount by which the mechanical 
properties outlined above are altered in heart failure, these studies indicate that mechanical 
parameters involved in thin filament activation and XB cycling are important components 
of the disease manifestation and therefore might contribute to the development of FORCE-
ALT. To elucidate if and how changes to mechanical parameters in human heart failure 
promote or modulate FORCE-ALT, we incorporated mechanical remodeling into the Rice 
et al myofilament model. Specifically, we altered thin filament activation, embodied in the 
Rice et al model by these 6 parameters: perm50, koffL, koffH, kon, kn_p, and kp_n. knpT and kpnT 
are nonlinear transition rates that are functions of these 6 parameters and represent calcium 
based activation of the thin filament, which is shown in Figure 4.1 as the transition of the 
thin filament from the NXB state (XB formation is inhibited) to the PXB state (weakly bound 
XB formation is possible). Specifically, perm50 is the half activation constant for shift of a 
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thin filament regulatory unit (RU) from NXB to PXB, koffH (koffL) is the rate constant for Ca2+ 
unbinding from the high (low) affinity binding site of Troponin C, and kon is rate constant 
for Ca2+ binding to Troponin C. kn_p and kp_n are constant scaling factors of the knpT and 
kpnT transition rates. We also altered XB cycling rates, expressed by these Rice et al 
parameters: fapp, gapp, hf, hb, and gxb. The rates fapp and gapp regulate the transition of the 
thin filament from the PXB state to the strongly bound XB state where the myosin head has 
not yet rotated and induced strain in the neck region (XBPreR). hf and hb are transition rates 
between the XBPreR and XBPostR state (thin filament is strongly bound to a XB which has a 
rotated myosin head and has induced distortion). gxb represents the ATP consuming 
transition rate from XBPostR to PXB. Due to the uncertainty in the literature regarding the 
exact amount that these parameters change in heart failure, as described above, we explored 
heart failure –induced remodeling of these 11 myofilament parameters within the range of 

























Required for alternans to occur 
perm50 0.5 (unitless) 









Largest effect on alternans 
magnitude 
kon 47.5 1/µMs 
Large effect on alternans 
magnitude 
koffH 25 1/s 
Large effect on alternans 
magnitude 
koffL 250 1/s 
Negligible effects on alternans 
magnitude 
kn_p 0.61 1/ms 
kp_n 0.016 1/ms 
fapp 4.8 1/ms 
gapp 0.093 1/ms 
hf 0.010 1/ms 
hb 0.035 1/ms 
gxb 0.030 1/ms 
Table 4.1 Control and Heart Failure Values for Important Model Parameters.  
Iup is from the ten Tusscher et al ionic model (ten Tusscher and Panfilov, 2006). All other 
parameters are from the Rice et al myofilament model (Rice et al., 2008). 
 
4.2.3 Alternans Protocol  
Clinical studies in patients with human heart failure have shown that APV-ALT 
arises at moderate pacing rates (Narayan et al., 2008); APV-ALT has also been induced, at 
these rates, in computational electrophysiological models of human myocytes and LV 
wedges with abnormal calcium handing by pacing the models with a dynamic pacing 
protocol (Bayer et al., 2010). To induce APV-ALT in our electromechanical model of the 
myocyte, we used a pacing protocol similar to that in Bayer et al. (Bayer et al., 2010). We 
first paced the myocyte at near resting pacing rates (850 ms; 71 bpm) until steady state was 
reached. Then, a dynamic pacing protocol was executed with pacing beginning at a cycle 
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length (CL) of 650 ms (92 bpm) and decreasing by 50 ms every 100 beats, until loss of 1:1 
capture occurred. 
Since our myocyte model is a strongly coupled electromechanical model, the 
procedure used to induce APV-ALT was also expected to result in the generation of 
FORCE-ALT. We aimed to test this hypothesis and to uncover the mechanism linking 
FORCE-ALT to APV-ALT. The pacing protocol also allowed us to probe the sensitivity 
of FORCE-ALT to CL. 
To elucidate if altered thin filament activation and XB cycling rates found in human 
heart failure exacerbated or alleviated FORCE-ALT, we examined how each remodeled 
parameter described above individually affected FORCE-ALT; 11 sets of simulations were 
thus run using the dynamic pacing protocol, each including the electrical remodeling and 
the remodeling of one of the myofilament parameters. To uncover the effect of disease 
severity for each remodeled myofilament parameter, each set of simulations consisted of 
41 unique simulations in which the chosen mechanical parameter was assigned a value in 
the range of 80% to 120% of its baseline value in Rice et al (incremented by 1%). To 
discover if FORCE-ALT can be induced by mechanical remodeling and dynamic pacing 
alone, the 451 simulations just described were executed again but without the inclusion of 
electrical remodeling. 
Finally, since active force generation is known to be modulated by sarcomere length 
(SL) (Gordon et al., 1966), we wanted to uncover if FORCE-ALT was also sensitive to SL. 
To do this, the aforementioned 451 simulations (with the electrical remodeling) were each 
run 16 times, during which we held SL constant at a different value for each simulation. 
SL values ranged from 1.65 µm to 2.4 µm, in increments of 0.05 µm. This range of SL 
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values was chosen because it is in the operating range for cardiac myocytes (Trayanova 
and Rice, 2011a).  
 
4.2.4 Alternans Analysis 
The magnitudes of alternans in active force, intracellular calcium concentration 
([Ca]i), and transmembrane voltage (Vm) were each calculated using the following formula 
commonly used in the quantification of alternans (Kockskamper and Blatter, 2002; Shkryl 
et al., 2012; Xie et al., 2013):  
 
 𝐴𝐿𝑇𝑀 = 1 − 
𝑆𝑚𝑎𝑙𝑙 𝐴𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒
𝐿𝑎𝑟𝑔𝑒 𝐴𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒
        
 
        (Equation 4.2) 
 
where Small Amplitude is the peak value minus the minimum value during the small beat 
and Large Amplitude is the peak value minus the minimum value during the large beat. 
Alternans magnitude was calculated for each pair of beats during the final 64 beats of each 
CL, following the approach in Bayer et al (Bayer et al., 2010) and the largest alternans 
magnitude per CL for each simulation was recorded. APV-ALT was calculated, as 
described above, during the period from the start of Phase II until the end of Phase III of 
the action potential. Alternans occurred if ALT > 0. 
 
4.3 Results 
4.3.1 Abnormal Intracellular Calcium Handling Results in Force Alternans  
Incorporating heart failure electrical remodeling in our strongly coupled cellular 
electromechanical model (as described in Methods) resulted, as expected, in intracellular 
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calcium alternans (CA-ALT) that caused action potential voltage alternans (APV-ALT), 
similar to those shown previously (Bayer et al., 2010; Narayan et al., 2008). An example 
of CA-ALT as a function of time and as superimposed beats is shown in Figure 4.2, panels 
A and E respectively, for pacing at a CL of 650 ms (92 bpm) and for a SL of 2.1 µm (a 
typical length during the normal cardiac cycle). The superimposed beats emphasize the 
presence of CA-ALT and the difference in the Ca2+ transient between the odd (small [Ca]i 
transient) and even (large [Ca]i transient) beats. The corresponding APV-ALT is shown in 
Figure 4.2, panels B and F. CA-ALT also induced alternans in active force (FORCE-ALT), 
shown as a function of time (Figure 4.2C) and as overlaid beats (Figure 4.2H). 
 
 
Figure 4.2 CA-ALT (column 1), APV-ALT (column 2), [Ca]Troponin (column 3), and 
FORCE-ALT (column 4) for simulations incorporating electrical remodeling in the 
absence of mechanical remodeling for a pacing CL of 650 ms and for SL=2.1 μm. 
Alternans are plotted over time in row 1 showing that CA-ALT was sufficient to produce 
APV-ALT, [Ca]Troponin alternans, and FORCE-ALT. Odd (blue) and even (red) beats from 
row 1 are superimposed to illustrate that the magnitude of alternans in rows 2 (strongly 
coupled simulations) and 3 (weakly coupled simulations) were different with and without 
myofilament feedback.  
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Due to myofilament feedback in our strongly coupled model (Figure 4.2, panels C 
and G), CA-ALT and APV-ALT differed from those obtained by Bayer et al and Narayan 
et al (Bayer et al., 2010; Narayan et al., 2008). We used the weakly coupled version of the 
model to explore the effects of myofilament feedback on CA-ALT, APV-ALT, and 
FORCE-ALT (compare rows 2 and 3 of Figure 4.2). The magnitudes of [Ca]i and CA-ALT 
(CA-ALTM) were both smaller in the strongly coupled model as compared to those in the 
weakly coupled ([Ca]i: 0.44 µM vs 0.50 µM for odd beat, 0.51 µM vs 0.68 µM for even 
beat; CA-ALTM: 21% vs 35%). Since Troponin C binds free intracellular calcium and thus 
removes those calcium ions from the pool of free calcium available in the cytoplasm 
([Ca]i), the feedback via the [Ca]Troponin term (Equation 4.1) in the strongly coupled model 
resulted in a smaller magnitude of [Ca]i. Smaller CA-ALTM was due to the fact that 
Troponin C buffers more [Ca]i when [Ca]i transient is large (even beat) than when it is 
small (odd beat), thus reducing the peak magnitude of [Ca]i during the even beat relative 
to that of the odd and consequently decreasing CA-ALTM, as calculated according to 
Equation 4.2. The magnitude of APV-ALT (APV-ALTM) was also smaller in the strongly 
coupled model (46% vs. 68% with no feedback) due to diminished CA-ALTM. The 
magnitude of [Ca]Troponin was smaller in the strongly vs weakly coupled model ([Ca]Troponin: 
8.73 µM vs 13.19 µM for odd beat, 14.86 µM vs 24.17 µM for even beat) due to diminished 
[Ca]i. The strong coupling also resulted in a smaller magnitude of the active force due to 
the decreased [Ca]i transient (0.18 vs 0.36 normalized force for odd beat, 0.46 vs 0.79 for 
even beat). However, the magnitude of FORCE-ALT (FORCE-ALTM) was 5% greater in 
the case of myofilament feedback than without (60% vs. 55%), despite the smaller CA-
ALTM in the former case. This was due to a smaller amount of calcium bound to Troponin 
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C during both the odd and even beats, resulting from the reduced [Ca]i in this case. Since 
calcium binding to Troponin C activates the thin filament, less thin filament regulatory 
units (RUs) transitioned from the non-permissive (NXB; XB formation is inhibited) to the 
permissive (PXB; weakly-bound XBs formation possible) state, (Figure 4.1) resulting in less 
RUs transitioning from PXB to the states with strongly-bound XBs (XBPreR and XBPostR). 
Since active force is generated by the rotation of the thick filament, fewer RUs in the pre-
rotated (XBPreR) state caused less RUs to transition from it to the post-rotated (XBPostR) 
state, producing less active force. However, since the presence of strongly bound XBs is 
known to enhance the binding affinity of Troponin C to calcium on nearby thin filament 
RUs and since Rice et al (Rice et al., 2008) incorporated this nonlinear cooperativity 
mechanism, the relatively smaller amount of strongly bound XBs during the odd (smaller 
[Ca]i) beat resulted in greater reduction of active force generation relative to the even 
(larger [Ca]i) beat. This resulted in enhanced FORCE-ALTM in the strongly coupled model 
as calculated according to Equation 4.2.  
 
4.3.2 Sensitivity of Alternans to Pacing Rate 
Simulations with our strongly coupled electromechanical myocyte model revealed 
that FORCE-ALTM has a non-monotonic dependence on CL (Figure 4.3A, solid line), 
with a local minimum at CL=400 ms. CA-ALTM monotonically increased with increased 
pacing rate, while APV-ALTM remained relatively small at slower pacing rates and 
increased at faster pacing rates (Figure 4.3B-C, solid line). No alternans occurred for 
pacing CLs>650 ms. An important observation here is that for all clinically relevant pacing 
rates (as discussed in the Introduction, <110 bpm; CL>=550 ms), CA-ALTM, ranging 
21%-31%, induced smaller APV-ALTM (ranging 46-48%) but larger FORCE-ALTM 
39 
 
(ranging 51-61%), consistent with the results presented in Figure 4.2. However, at faster 
pacing rates (CL<500 ms), larger CA-ALTM induced smaller FORCE-ALTM. This was 
due to elevated [Ca]i, which occurred due to a buildup of diastolic intracellular calcium as 
a result of insufficient time between beats for the SERCA pump and the Na/Ca2+ exchanger 
to restore [Ca]i to normal. During the large (even) beat, this abnormally large [Ca]i transient 
saturated Troponin C prior to reaching its peak magnitude, preventing additional free 
calcium from binding to Troponin C and thus preventing an increase in thin filament 
activation. This prevented further thin filament RUs from transitioning to the PXB, XBPreR 
and XBPostR states from the NXB state (Figure 4.1). Since no additional rotation of the thick 
filament occurred, no added active force was generated during the even beat, despite 
additional free calcium becoming available as the [Ca]i transient increased from the value 
at which Troponin C saturated to its peak magnitude. This resulted in diminished FORCE-
ALTM at faster pacing rates, according to Equation 4.2.  
 
 
Figure 4.3 Dependence of FORCE-ALTM (A), CA-ALTM (B), and APV-ALTM (C) to 
CL in simulations with electrical remodeling in the absence of mechanical remodeling at 
SL=2.1 μm for both the strongly (solid lines) and weakly coupled (dashed lines) models. 
The purple dashpot line indicates where the data in Figure 4.4 are taken from (CL=600 
ms). No alternans occurred for pacing CLs>650 ms for either the strongly or weakly 
coupled model.  
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Eliminating myofilament feedback reduced FORCE-ALTM at all CLs on average 
by 11%, flattened the CA-ALTM dependence, and increased APV-ALTM (Figure 4.3A-
C, dashed line), rendering the latter similar to the dependence documented by Bayer et al 
and Narayan et al (Bayer et al., 2010; Narayan et al., 2008). CA-ALTM was smaller for 
the strongly verses the weakly coupled model at slower pacing rates (CL>450 ms), 
consistent with the results presented in Section 3.1 for CL=650 ms (Figure 4.2). However, 
CA-ALTM became larger than that for the weakly coupled model at faster pacing rates 
(CL<400 ms) due to diminished myofilament feedback during the even but not the odd 
beat. As CL decreased, [Ca]i, was elevated and saturated Troponin C during the even beat, 
preventing both additional free calcium from binding to Troponin C, and additional thin 
filament RUs from transitioning from the NXB to the PXB and strongly-bound XB states, as 
discussed in the preceding paragraph. Since [Ca]Troponin is a function of the amount of 
calcium bound to Troponin C and of the number of RUs in the strongly-bound XB states, 
myofilament feedback was diminished during the even beat more than the odd, thus 
reducing the magnitude of [Ca]i more during the odd beat. This resulted in larger CA-
ALTM for the strongly coupled model at faster rates. 
 
4.3.3 Dependence of Force, Calcium and Voltage Alternans on Sarcomere 
Length 
Simulations with our strongly coupled electromechanical myocyte model showed 
that, alternans magnitude changed as SL decreased from 2.4 to 1.65 µm. An example of 
the dependence of the three types of alternans magnitude on SL functions for pacing at a 
CL of 600 ms (100 bpm) is shown in Figure 4.4A-C, solid line. CA-ALTM increased for 
SL>2.05 µm (in Figure 4.4B) due to diminished myofilament feedback during the even 
41 
 
beat only, which occurred as a result of a progressive increase in the fraction of single-
overlap thin filament apposing the thick filament as SL increased. Since this portion of the 
thin filament has a higher binding affinity to calcium, a larger fraction of it caused greater 
calcium-Troponin C binding for a given [Ca]i. This progressively lowered the [Ca]i 
threshold at which Troponin C became saturated, preventing additional free calcium from 
binding to Troponin C, despite the peak magnitude of the [Ca]i transient being greater than 
the [Ca]i threshold for saturation. This saturation only occurred during the even beat due 
to its larger [Ca]i magnitude. Since [Ca]Troponin is a function of the amount of calcium bound 
to Troponin C, myofilament feedback was increasingly diminished at progressively larger 
SLs during the even beat relative to the odd, thus steadily reducing the magnitude of [Ca]i 
during the even beat (according to Equation 4.1). This resulted in progressively larger CA-
ALTM, according to Equation 4.2, at increasingly greater SLs for SL>2.05 µm. The 
saturation of Troponin C during the even beat also prevented enhanced thin filament 
activation, which, as described in Section 3.2., resulted in progressively diminished 
FORCE-ALTM, as shown for SL increasing above 2.05 µm in Figure 4.4A. APV-ALTM 
decreased for SL>2.05 µm, despite increased CA-ALTM, due to increasingly diminished 
[Ca]Troponin during the even beat (as described above), which caused the [Ca]i transient 
during the even beat to have a notched appearance similar to Figure 4.2A (red lines). As 
SL increased, the [Ca]i magnitude prior to the [Ca]i notch became increasingly large (due 
to reduced [Ca]Troponin), causing CA-ALTM to increase in accordance with Equation 4.1. 
However, the [Ca]i transient quickly decreased from the peak value preceding the notch in 
[Ca]i to an increasingly smaller value as SL increased, thus shortening Phase II of the action 
potential and reducing its magnitude during the even beat and inducing smaller APV-
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ALTM. CA-ALTM also increased for SL<2.05 µm. As SL became progressively smaller, 
the fraction of single-overlap thin filament that was apposed to thick filament decreased, 
causing reduced calcium-Troponin C binding for a given [Ca]i. This diminished thin 
filament activation and decreased the number of RUs that transitioned from NXB to PXB, 
thus reducing the number of RUs that transitioned to strongly-bound XB states. Since 
[Ca]Troponin is a function of the amount of calcium bound to Troponin C and of the number 
of RUs in the strongly-bound XB states, myofilament feedback was progressively 
diminished during the even relative to the odd beat as SL decreased, thus increasing the 
magnitude of [Ca]i more during the even beat. This resulted in progressively larger CA-
ALTM as SL decreased for SL<2.05 µm. FORCE-ALTM and APV-ALTM were large at 
SL<2.05 µm due to large CA-ALM. The trends for CA-ALTM and APV-ALT as functions 
of SL were different at slow and fast pacing rates (Figure 4.4E-F), while the dependence 




Figure 4.4 Sensitivity of FORCE-ALTM (A), CA-ALTM (B), and APV-ALTM (C) to SL 
in simulations with electrical remodeling in the absence of mechanical remodeling at 
CL=600 ms for both the strongly (solid lines) and weakly (dashed lines) coupled models. 
Plots of the dependence of FORCE-ALTM (D), CA-ALTM (E), and APV-ALTM (F) on 
SL are shown for slow and fast pacing rates for the strongly coupled model. The purple 
dashpot line indicates where the data displayed in Figure 4.3 are from (SL=2.1 μm).  
 
Eliminating myofilament feedback expanded the range of FORCE-ALTM (Figure 
4.4A, dashed line) without altering the shape of its dependence on SL. As expected, the 
removal of myofilament feedback rendered CA-ALTM and APV-ALTM insensitive to SL 
changes (Figure 4.4B-C, dashed line). FORCE-ALTM was larger in the weakly coupled 
model at SL<2.0 µm due to larger CA-ALTM; it was smaller at SL>2.0 µm due to 
enhanced saturation of Troponin C caused by the larger [Ca]i magnitudes shown to occur 
in the weakly coupled model (Figure 4.2I). This resulted in smaller peak active force 
generation during the even beat and thus diminished FORCE-ALTM (via Equation 4.2) in 




4.3.4 Effect of Heart Failure Induced- Remodeling of Mechanical Parameters 
on Force, Calcium and Voltage Alternans  
Incorporating heart failure induced-remodeling of both electrical and mechanical 
parameters in simulations with our strongly coupled electromechanical myocyte model 
demonstrated that of the mechanical parameters involved in thin filament activation and 
XB cycling, only remodeling in perm50 (half activation constant for shift of a thin filament 
RU from NXB to PXB), koffH (rate constant for Ca2+ unbinding from the high affinity binding 
site of Troponin C), and kon (rate constant for Ca2+ binding to Troponin C) caused 
appreciable alterations in FORCE-ALTM, CA-ALTM, and APV-ALTM. Of these three, 
perm50 was the most important because changes to it had the most profound effects on 
FORCE-ALTM, CA-ALTM, and APV-ALTM. Examples of these functions are shown in 
Figure 4.5 for perm50 (row 1), koffH (row 2), and kon (row 3) for pacing at a CL of 600 ms 
and SL of 2.1 µm, where each remodeled parameter is displayed as a percent of its normal 
value. By definition, increasing perm50 diminishes thin filament activation. As perm50 was 
progressively increased above 102%, thin filament activation was increasingly reduced, 
which steadily increased CA-ALTM, FORCE-ALTM and APV-ALTM, via the 
mechanisms described in Section 3.3 for SL<2.05 µm. As perm50 was decreased below 
102%, thin filament activation was increasingly enhanced, which increased the transition 
rate of NXB to PXB and decreased the reverse rate, causing more RUs to transition to PXB. 
A greater number of RUs in the PXB state induced additional RUs to transition to the 
strongly-bound XB states, increasing the fraction of total RUs with strongly-bound XBs. 
Therefore, achieving the maximum fraction of RUs in the XBPreR and XBPostR states could 
be attained with increasingly less activating calcium as perm50 decreased. Since [Ca]Troponin 
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is a function of the fraction of total RUs in strongly-bound XB states and since during the 
even beat [Ca]i was large enough to attain that maximum fraction, myofilament feedback 
was progressively diminished during the even relative to the odd beat as perm50 decreased, 
thus increasing the magnitude of [Ca]i more during the even beat. This caused 
progressively larger CA-ALTM. Active force, which is also a function of the fraction of 
total RUs in strongly-bound XB states, was progressively diminished during the even 
verses the odd beat (similar to [Ca]Troponin), which resulted in progressively smaller 
FORCE-ALTM, despite enhanced CA-ALTM, as perm50 decreased. APV-ALTM was 
enhanced due to larger CA-ALTM. By definition, a decrease in koffH or an increase in kon 
increases the binding affinity of Troponin C to calcium. As koffH was progressively 
decreased below 103% and kon increased above 92%, binding affinity was increased (thus 
enhancing calcium-Troponin C binding for a given [Ca]i), which progressively enhanced 
CA-ALTM and diminished FORCE-ALTM and APV-ALTM, in the same manner as 
described in Section 3.3. for SL>2.05 µm. koffH>103% and kon<92% decreased the binding 
affinity of Troponin (thus diminishing thin filament activation), which progressively 
increased CA-ALTM, FORCE-ALTM and APV-ALTM as described in Section 3.3 for 
SL<2.05 µm. Removing myofilament feedback decreased FORCE-ALTM for nearly all 
values of perm50, koffH, and kon (Figure 4.5, column 1, dashed line), and as expected, 
rendered CA-ALTM and APV-ALTM insensitive to remodeling of those mechanical 
parameters. FORCE-ALTM was diminished due to enhanced saturation of Troponin C 
caused by the larger [Ca]i magnitudes occurring in the weakly coupled model (Figure 4.2I) 





Figure 4.5 Dependence of FORCE-ALTM (column 1), CA-ALTM (column 2), and APV-
ALTM (column 3) on the level of mechanical remodeling for pacing CL=600 ms and 
SL=2.1 μm for the strongly coupled model (solid lines). Dashed line in the FORCE-ALTM 
refers to the weakly coupled model. Heart-failure remodeling mechanical parameters 
perm50 (row 1), koffH (row 2), and kon (row 3), are displayed as a percent of their normal 
values.  
 
Finally, simulations were run incorporating only mechanical remodeling (no 
electrical remodeling). For all CLs and SLs studied, there was no FORCE-ALT, 
demonstrating that abnormal intracellular calcium handling and thus CA-ALT was 





The present study examines the cellular mechanisms underlying the formation of 
pressure alternans (FORCE-ALT) in the presence of MTWA (APV-ALT), which have 
been shown to be predictors of worsening heart failure and lethal ventricular arrhythmias, 
respectively. The goals of this study were to uncover the mechanisms linking APV-ALT 
and FORCE-ALT in failing human myocytes and to investigate how the link between those 
alternans was affected by pacing rate and various physiological conditions. Using a 
strongly coupled human electromechanical myocyte model, we showed that CA-ALT, 
induced by decreased Iup, was the link between APV-ALT and FORCE-ALT and that 
FORCE-ALTM was largest at clinically-relevant slow to moderate pacing rates (<110 
bpm), where APV-ALT was smallest. We found that FORCE-ALTM, CA-ALTM and 
APV-ALTM were altered by heart failure induced-remodeling of mechanical parameters 
and by sarcomere length; this was due to the presence of myofilament feedback. Together 
these findings link FORCE-ALT to APV-ALT and suggest that pressure alternans is 
directly linked to MTWA via calcium dysregulation and may be a better predictor of the 
propensity for ventricular arrhythmias at clinically relevant pacing rates (<110 bpm).  
 
4.4.1 Calcium Alternans Link Action Potential Voltage Alternans to Force 
Alternans 
MTWA is caused by CA-ALT predominantly as a result of decreased sarcoplasmic 
reticulum calcium uptake current (Iup) in heart failure patients at near resting heart rates 
(Bayer et al., 2010; Narayan et al., 2008). In addition, MTWA and pressure alternans have 
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been shown to occur simultaneously in patients at such pacing rates (Selvaraj et al., 2011). 
Furthermore, patients with pressure alternans have significantly lower amounts of 
sarcoplasmic reticulum Ca2+-ATPase (SERCA) mRNA than patients without (Hirashiki et 
al., 2010; Hirashiki et al., 2006). Finally, FORCE-ALT, the cellular manifestation of 
pressure alternans, has been found to be regulated by calcium dysregulation in animal 
experiments with cardiac muscle preparations (Kihara and Morgan, 1991; Kotsanas et al., 
1996; Lab and Lee, 1990; Orchard et al., 1991) and perfused hearts (Brooks et al., 1994; 
Lee et al., 1988), paced at fast rates. Taken together, the results from these previous studies 
have suggested that CA-ALT, due to reduced Iup, is a likely candidate to underlie FORCE-
ALT in human heart failure. Our results presented here provide the proof that CA-ALT, 
via reduced Iup, drove the formation of FORCE-ALT at clinically relevant pacing rates.  
 
4.4.2 Force Alternans Are Large at Slow Pacing Rates and May Be 
Undetectable at Faster Pacing Rates 
Studies have shown that the mean heart rate onset at which pressure alternans were 
first detected in pacing studies was 606 ms (99 bpm) (Hirashiki et al., 2006), and 517 to 
571 ms (116 bpm – 105 bpm) (Selvaraj et al., 2011). In addition, a study conducted during 
normal sinus rhythm found that patients with pressure alternans had significantly slower 
heart rates than those without (81.0 bpm vs 93.1 bpm) (Kim et al., 2014). That same study 
also showed that patients with both MTWA and pressure alternans had slower heart rates 
than those with only MTWA (81.0 bpm vs 92 bpm, not statistically significant), suggesting 
that patients with only MTWA may have had small yet undetectable pressure alternans due 
to the alternans magnitude being markedly reduced at faster heart rates. One study further 
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supported this hypothesis by showing that the amplitude of pressure alternans declined at 
increasingly faster pacing rates for four patients, three of whom  lost pressure alternans 
when pacing rates exceeded 120, 130 and 140 bpm (500, 462, 400 ms) respectively 
(Kashimura et al., 2013). The present study provided support of this finding, since we 
demonstrated that FORCE-ALTM was greatest at slower pacing rates (>109 bpm) and 
declined significantly at faster pacing rates (<109 bpm). However, the outcome of one 
study contradicted these findings and reported that the magnitude of pressure alternans 
increased from 600 ms to 500 ms (Selvaraj et al., 2011). This conflicting evidence might 
have arisen from the method of calculating pressure alternans magnitude in that study, 
which differed from ours (spectral analysis versus measuring the amplitude change 
between the odd and even beats). To date, few patient studies have investigated the effects 
of pacing rate on the detection and magnitude of pressure alternans. However, as we have 
shown, pacing rate affects FORCE-ALTM and could explain why some patients with 
MTWA do not have detectable pressure alternans despite having underlying abnormal 
calcium handling. Additional studies of pressure alternans in heart failure patients are 
needed to investigate this phenomenon in greater detail.  
 
4.4.3 Implications of Heart Failure-Induced Mechanical Remodeling for 
Alternans Severity 
Studies have shown that thin filament activation can be altered in human heart 
failure. Specifically, decreased phosphorylation of cardiac Troponin I has been shown to 
be significantly decreased in human heart failure (Messer et al., 2007; Zaremba et al., 
2007), resulting in reduced sliding speed and an increased Ca2+-sensitivity. Although this 
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change in thin filament activation has been observed in human heart failure, to date no 
studies have investigated whether it is reduced in patients with pressure alternans or 
MTWA. Here we demonstrated that heart failure-induced mechanical remodeling of 
parameters that modify thin filament activation can both exacerbate and diminish FORCE-
ALT, CA-ALT, and APV-ALT. These results could explain the results of some studies 
which have revealed two different populations of patients with alternans: those with both 
MTWA and pressure alternans and those with only MTWA (Kim et al., 2014; Kodama et 
al., 2001; Selvaraj et al., 2011). The patient population with both types of alternans could 
have calcium handling abnormalities and reduced thin filament activation, which would 
(as our results suggest) result in larger and thus more easily detectable pressure alternans. 
The patients in which only MTWA were detectable may either have less severe reductions 
in thin filament activation or no abnormalities at all, and thus have smaller and undetectable 
pressure alternans. Furthermore, one study has shown that the magnitude of MTWA in 
patients with both MTWA and pressure alternans is larger than in patients with only 
MTWA (Kim et al., 2014), suggesting that if those patients had reduced thin filament 
activation as we speculated, then that would enhance the magnitude of MTWA, in 
agreement with our results (Figure 4.5).  
 
4.5 Conclusions 
APV-ALT and FORCE-ALT are linked via CA-ALT, resulting from reductions in 
sarcoplasmic reticulum calcium uptake current, in a strongly coupled electromechanical 
model of the failing human myocyte. Our results demonstrate that the magnitude of 
FORCE-ALT is largest at clinically relevant pacing rates (<110 bpm), where APV-ALT 
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was smallest. The magnitudes of FORCE-ALTM, CA-ALTM and APV-ALTM were 
dependent on pacing rate. Due to myofilament feedback, the magnitude of the alternans 
was also dependent on sarcomere length, and on the level of heart failure induced-
remodeling of mechanical parameters involved in thin filament regulation. These findings 
provide important insight into the cellular mechanisms underlying pressure alternans at 
clinically relevant pacing rates (<110 bpm) and may aid in investigating whether pressure 
alternans is an improved and reliable predictor of propensity for ventricular arrhythmias in 









Chapter 5 Study 2: 
Myofilament Protein Dynamics 





This study has been published in Progress in Biophysics and Molecular Biology 
(Zile and Trayanova, 2017) and reprinted with permission from Elsevier publishing. 
 
5.1 Introduction 
Hypertrophic cardiomyopathy (HCM), defined by unexplained ventricular 
hypertrophy, is the most commonly inherited cardiac disease, with a reported prevalence 
of 1 in 500 worldwide (Maron et al., 1995; Maron and Maron, 2013). Although the annual 
mortality from HCM is low (0.5 – 2%) (Elliott et al., 2014; Maron et al., 2014), certain 
patient subsets, such as young athletes, have enhanced risk of sudden cardiac death (SCD) 
(Maron et al., 2014; Maron et al., 2007). Thus far, the only treatment proven to prolong life 
and prevent SCD in HCM patients is implantation of a cardioverter defibrillator (ICD) 
(Gersh et al., 2011; Maron and Maron, 2013; Maron et al., 2003; Maron et al., 2000; Maron 
et al., 2013; Maron et al., 2007; Schinkel et al., 2012; Vriesendorp et al., 2013). The main 
risk markers used to identify those patients who will benefit most from an ICD include 
family history of HCM SCD, unexplained syncope, multiple-repetitive non-sustained 
ventricular tachycardia (NSVT) episodes, abnormal exercise blood pressure response, late 
gadolinium enhancement ≥15% of left ventricular mass, and massive left ventricular 
hypertrophy ≥ 30 mm (Gersh et al., 2011; Maron, 2002; Maron, 2010; Maron and Maron, 
2013; Maron et al., 2003; Spirito et al., 2014; Spirito et al., 2009; Spirito et al., 2000). 
However, HCM patients who lack all risk factors are still not immune to SCD (Pastore et 
al., 1999; Spirito et al., 2014). In addition, the risk stratification models used to identify 
high risk adult patients are not as effective at identifying children with high risk (Maron et 
al., 2013). Furthermore, since SCD risk in HCM patients is highest in younger patients 
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(<30 years old) (Maron et al., 2014), ICDs must be implanted early in life, increasing the 
likelihood that those individuals will experience device-related complications (Maron et 
al., 2013). Despite the challenges of SCD risk stratification in young HCM patients and 
their increased probability of device complications, other treatment options are limited. In 
fact despite wide prevalence, many consider HCM an orphan condition because it lacks 
disease-specific pharmacological treatment (Spoladore et al., 2012), which may be a 
consequence of the wide genetic and phenotypic heterogeneity among HCM patients. In 
particular, more than 1500 mutations identified on at least 11 genes, encoding thick and 
thin myofilament protein components, have been found to underlie HCM (Bos et al., 2009; 
Ingles et al., 2013; Maron et al., 2012; Niimura et al., 1998; Seidman and Seidman, 2011), 
though the causality and contribution to disease progression for each is not fully understood 
(Bezzina et al., 2015). To complicate matters, a new HCM subgroup, described as 
‘genotype positive-phenotype negative,’ has been discovered in which patients have one 
or more pathogenic mutations but no disease phenotype (Gersh et al., 2011; Gray et al., 
2011; Maron and Semsarian, 2010; Maron et al., 2011). The lack of disease-specific 
pharmacological treatment, the challenges of accurately stratifying HCM SCD patients, 
and the incomplete understanding of the relationship between HCM genotype, phenotype 
and outcome (Charron et al., 2010) underscore the need to improve SCD prevention 
strategies for HCM patients by improving our understanding of how sarcomeric mutations 
in HCM patients contribute to the enhanced arrhythmogenesis underlying SCD (Coppini 
et al., 2013; Maron et al., 2000).  
Patients with HCM often have cardiac arrhythmias, including atrial fibrillation, 
NSVT, and sustained ventricular tachycardia, as well as prolonged QTc (Coppini et al., 
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2013; Coppini et al., 2014; Maron et al., 2000). Early afterdepolarizations (EADs), defined 
as a slowing or reversal of normal repolarization during the plateau or rapid depolarization 
phases, have been implicated as the primary mechanism underlying many arrhythmias 
associated with HCM (Weiss et al., 2010; Yan et al., 2001) and have also been found in 
patients with HCM (Coppini et al., 2013). Many studies have investigated the ionic 
mechanisms of EADs in lethal ventricular arrhythmias and have found that EADs occur 
when repolarization reserve is reduced due to enhanced inward current, diminished 
outward current, or both. In addition, there must also be a regenerative increase in net 
inward current that has the ability to overcome and reverse repolarization. The ion channels 
typically implicated in this positive feedback are the L-type Ca2+ current (ICaL) and the Na+-
Ca2+ exchange current (INaCa) (Weiss et al., 2010). New studies have also begun to explore 
the ionic mechanisms of EADs in human HCM tissue, finding that ICaL and INaCa play an 
important role along with the rapid delayed rectifier current (IKr), the late Na+ current (INaL), 
and Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Coppini et al., 2013).  
Although the ionic mechanisms of EADs have been studied, whether there are also 
myofilament protein dynamics mechanisms at play is poorly understood. Since 
mechanoelectric feedback (MEF) is known to be essential for normal function of the heart 
and is believed to be important in disease (Quinn, 2014; Taggart and Sutton, 1999; Tardiff 
et al., 2015; Zile and Trayanova, 2016) and since HCM is a disease caused by sarcomeric 
mutations, it is important to explore whether myofilament protein dynamics mechanisms 
could also contribute to EADs in human HCM. Thus, our goal was to utilize the capability 
of mechanistic computer simulations to investigate whether myofilament protein dynamics 
mechanisms modulate EAD formation in HCM for varying degrees of reduced 
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repolarization reserve, and to uncover how these mechanisms are affected by pacing rate, 
sarcomere length, and the degree of HCM-induced myofilament remodeling. 
 
5.2 Methods 
5.2.1 Human Electrophysiology-Force Myocyte Model 
To investigate whether myofilament protein dynamics mechanisms modulate EAD 
formation under the conditions of human HCM, a mechanistically-based human 
electrophysiology-force myocyte model was used. The electrophysiology-force model 
combined the human endocardial ventricular membrane kinetics model by Vandersickel et 
al (Vandersickel et al., 2014) and the myofilament protein dynamics model by Rice et al 
(Rice et al., 2008). The Vandersickel et al model, an extension of the ten Tusscher et al 
model (ten Tusscher and Panfilov, 2006), which incorporates updated L-type Ca2+ channel 
kinetics, was used because it is capable of generating EADs during reduced repolarization 
reserve. The Rice et al model, which describes the activation of the thin filament by 
intracellular calcium binding to Troponin C as well as thin filament binding to thick 
filament crossbridges (XBs) using a 6 state Markov model, was chosen for its 
computational efficiency and incorporation of important biophysical detail and 
cooperativity mechanisms. Since the Rice et al myofilament model was developed based 
on rabbit data, we adjusted it to match human force data as described elsewhere (Zile and 
Trayanova, 2016).  
The ionic and myofilament models were bidirectionally coupled by incorporating 
MEF on calcium dynamics (Figure 5.1); this was done by incorporating a dynamic term 
for troponin buffering of intracellular calcium ([Ca]Troponin) using our previously developed 
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approach (Zile and Trayanova, 2016) where we refer to this as “strong coupling.” In 
summary, the following equation was used to update the intracellular calcium 
concentration in the ionic model, using the [Ca]Troponin term calculated by the myofilament 
model, at each time step: 
 
 [𝐶𝑎]𝑇𝑜𝑡𝑎𝑙 =  [𝐶𝑎]𝑖 + [𝐶𝑎]𝐶𝑎𝑙𝑚𝑜𝑑𝑢𝑙𝑖𝑛 + [𝐶𝑎]𝑇𝑟𝑜𝑝𝑜𝑛𝑖𝑛                     
 (Equation 5.1) 
 
where [Ca]Total is the total calcium in the cytoplasm, [Ca]i is the free calcium in the 
cytoplasm, [Ca]Calmodulin is the total calcium buffered by calmodulin in the cytoplasm, and 
[Ca]Troponin is the total calcium bound to Troponin C and incorporates the cooperativity of 
calcium-troponin binding due to strongly bound nearby XBs. Bidirectionally coupling the 
models with a dynamic representation of [Ca]Troponin was important and necessary, because 
it has been shown to be crucial for accurately reproducing contractile experiment data in 




Figure 5.1 Ionic (A) and Myofilament (B) models combined to form the Bidirectionally 
Coupled Human Electrophysiology-Force Myocyte Model (C). A modified version of the 
ten Tusscher ionic model from Vandersickel et al (Vandersickel et al., 2014) was used for 
the ionic model. A modified version of the Markov state diagram of the myofilament model 
from Rice et al, which describes thin filament activation via free intracellular calcium 
([Ca]i) binding to Troponin C as well as thin filament binding to thick filaments to form 
crossbridges (XBs), was used for the myofilament model. The transition rates (knpT and 
kpnT) between the thin filament states where XB formation is inhibited (NXB) and where 
weakly bound XB formation is possible (PXB) are both functions of perm50, kon, koffH, and 
koffL. The rate knpT is also dependent on kn_p, and kpnT is additionally dependent on kp_n. The 
XBPreR and XBPostR states represent a thin filament with a strongly bound XB that do not 
and do, respectively, have rotated myosin heads which induced strain (Rice et al., 2008). 
Bidirectional coupling was obtained by incorporating MEF on calcium dynamics via 
Equation 5.1, where the total cytoplasmic calcium ([Ca]Total) is equal to the sum of [Ca]i, 
the total calcium bound to calmodulin ([Ca]Calmodulin), and the total calcium bound to 
troponin C ([Ca]Troponin).  
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A unidirectionally coupled version of the model (with no MEF and referred to as 
“weakly coupled” in our previously developed approach (Zile and Trayanova, 2016)) was 
created by removing the [Ca]Troponin term from Equation 5.1. The sole purpose of this model 
was to aid in examining how MEF altered EAD emergence and the frequency of EAD 
occurrence, by comparing its simulations to those of the bidirectionally coupled model. 
 
5.2.2 Incorporating HCM-Induced Remodeling 
We simulated human HCM in our single cell electrophysiology-force models by 
incorporating ionic and myofilament remodeling. Ionic remodeling was represented by 
reducing repolarization reserve. Specifically, we increased the maximal conductance of the 
L-type Ca2+ current (GCaL) 2.5-5 fold (0.05 increments) and decreased the maximal 
conductance of the rapid delayed rectifier current (GKr) to 10-100% of its baseline value 
(in increments of 0.1%) in the ten Tusscher et al model, similar to Vandersickel et al 
(Vandersickel et al., 2014) and Zimik et al (Zimik et al., 2015) to represent increased ICaL 
density, CaV1.2 protein and CaCNA1.2, and decreased IKr density and HERG1b observed 
in human HCM (Coppini et al., 2013). These specific features of HCM remodeling were 
incorporated because they have been shown to be important to the development of EADs 
in previous studies of human HCM (Coppini et al., 2013). A range of values was used 
because HCM remodeling has been shown to be progressive over time (Gersh et al., 2011; 
Semsarian et al., 1997).   
Myofilament remodeling was incorporated to simulate altered thin filament 
activation and myofilament Ca2+ sensitivity found in human HCM. Changes in thin 
filament activation have been linked to altered phosphorylation of cardiac Troponin I 
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(cTnI) (Messer et al., 2007), mutations in cardiac troponin T (cTnT) (Miller et al., 2001) 
and mutations in cardiac myosin binding protein C (cMyBP-C) (Carrier et al., 2015; 
Kampourakis et al., 2014; Mun et al., 2014; Previs et al., 2015; Sequeira et al., 2015; 
Witayavanitkul et al., 2014), which occur in HCM in humans (Carrier et al., 2015; Sequeira 
et al., 2015) and animals (Miller et al., 2001; Warren et al., 2015). Although there are more 
sarcomeric mutations that cause HCM, such as in cardiac actin (ACTC), cardiac troponin 
C (TNNC1), and α-tropomyosin (TPM1) (Olivotto et al., 2015), less is known about how 
these affect thin filament activation, if at all. Furthermore, myocardial Ca2+ sensitivity, 
defined as the amount of Ca2+ necessary to produce half maximal force, is a function of 
thin filament activation and XB cycling rates and has been shown to be altered in HCM. 
Myocardial Ca2+ sensitivity has been found to increase by 1-7% in human HCM (Coppini 
et al., 2013; Robinson et al., 2007; Warren et al., 2015) and by 3-10% in animal models of 
HCM (Miller et al., 2001).  
Despite the lingering uncertainty in the mechanisms by which these sarcomeric 
mutations lead to the altered myofilament properties outlined above and the uncertainty of 
the exact amount by which the myofilament properties are altered in HCM, these studies 
indicate that myofilament parameters involved in thin filament activation and Ca2+ 
sensitivity are important components of the disease manifestation and therefore may 
contribute to the emergence of EADs. To elucidate if and how changes to myofilament 
parameters in human HCM promote the emergence of EADs or modulate the frequency of 
EAD occurrence, we incorporated HCM remodeling into the Rice et al myofilament model. 
Specifically, we altered thin filament activation, embodied in the Rice et al model by these 
3 parameters: perm50, koffH, and kon. The parameters knpT and kpnT are nonlinear transition 
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rates that are functions of these 3 parameters and represent nearby regulatory unit (RU)-
based and calcium-based activation of the thin filament, which is shown in Figure 5.1 as 
the transition of the thin filament from the NXB state (XB formation is inhibited) to the PXB 
state (weakly bound XB formation is possible). The parameter perm50 is the half activation 
constant for the shift of a thin filament RU from NXB to PXB, koffH is the rate constant for 
Ca2+ unbinding from the high affinity binding site of Troponin C, and kon is rate constant 
for Ca2+ binding to Troponin C. Due to the uncertainty in the literature regarding the exact 
amount that these parameters change in HCM, as described above, we explored HCM –
induced remodeling of these 3 myofilament parameters within the range of 85% to 115% 




















Effect of HCM 










Increase necessary for EAD 
Emergence 
GKr 0.153 nS/pF 







Decrease necessary for EAD 
Emergence 













koffH 25 1/s Increase 
kon 47.5 1/µMs Decrease 
Table 5.1 Baseline and HCM Values for Important Model Parameters.  
GCaL and GKr are from the ten Vandersickel et al ionic model (Vandersickel et al., 2014). 
perm50, kon, and koffH are from the Rice et al myofilament model (Rice et al., 2008). 
 
5.2.3 EAD Protocol  
Studies of cardiomyocytes from HCM patients have shown that EADs arise at 
pacing frequencies ranging from 0.25-1 Hz  (Coppini et al., 2013), consistent with clinical 
studies in which arrhythmias arose in HCM patients who were sedentary, asleep, or 
performing normal daily activities (Maron et al., 1994; Maron et al., 2009); EADs have 
also been induced, at these rates, in computational electrophysiological models of human 
ventricular arrhythmias associated with HCM (Vandersickel et al., 2014; Zimik et al., 
2015). To induce EADs in the bidirectionally and unidirectionally coupled HCM 
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electrophysiology-force myocyte models, we used a pacing protocol similar to those in 
Zimik et al (Zimik et al., 2015) and Vandersickel et al (Vandersickel et al., 2014). We 
isometrically paced the myocyte models at one of three pacing cycle lengths (CLs) (1000 
ms; 1Hz, 2000 ms; 0.5 Hz, or 4000 ms; 0.25 Hz) for 100 beats. After the first 50 beats, all 
of our simulations had reached steady state, similar to previous studies (Zile and 
Trayanova, 2016). The final 50 beats were used to analyze the emergence of EADs and the 
frequency of their occurrence. Since sarcomere length (SL) changes during the cardiac 
cycle (ranging from 1.70 – 2.40 µm) (Trayanova and Rice, 2011a) and since it is known to 
modulate MEF (Zile and Trayanova, 2016), isometric simulations for each pacing rate were 
run three times, once at a constant SL of 1.70, 1.90 or 2.40 µm.  
To determine if MEF modifies EAD formation for varying degrees of HCM-
induced reduced repolarization reserve in HCM myocytes, we compared EAD formation 
in simulations with the bidirectionally vs unidirectionally coupled HCM myocyte models 
using the protocol above. Since there is a wide spectrum of HCM-induced myofilament 
remodeling (including no myofilament remodeling at all) (Gersh et al., 2011; Gray et al., 
2011; Maron and Semsarian, 2010; Maron et al., 2011), we first compared simulations with 
and without feedback that incorporated only HCM-induced ionic remodeling.  
Then, to elucidate how the severity of HCM-induced myofilament remodeling 
alters the effects of MEF on EAD formation, we compared bidirectionally coupled 
simulations with only HCM-induced ionic remodeling (described above) to those with 
HCM-induced ionic remodeling and different amounts of HCM-induced myofilament 
remodeling (described below) using the aforementioned protocol. To incorporate different 
amounts of HCM-induced myofilament remodeling in the simulations, one of the 3 
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myofilament parameters (perm50, koffH, kon) was assigned a value 5-15% below or above 
its baseline value (as described in the previous section) for a given simulation. 
 
5.2.4 Analysis of EADs 
An EAD was defined as a slowing or reversal of normal repolarization during the 
plateau or rapid depolarization phases (phases 2 or 3) of an action potential (AP) 
(Vandersickel et al., 2014; Weiss et al., 2010). We narrowed this definition by requiring 
that the spontaneous depolarization(s) in phase 2 or 3 be larger than 1 mV. Therefore, an 
EAD was said to be elicited in a simulation if at least 1 of the final 50 APs had at least one 
spontaneous depolarization(s) in phase 2 or 3 that was larger than 1 mV. 
The frequency of EAD occurrence was calculated as the number of beats that 
elicited an EAD. Specifically,  
 
frequency of EAD occurrence =  
# of action potentials with 1 or more EADs 
total number of beats
                    
                   
(Equation 5.2) 
 
where the total number of beats were defined as the final 50 beats of each simulation. 
 
5.3 Results 
5.3.1 MEF Alters EAD Emergence and Frequency of Occurrence 
 Incorporating HCM-induced repolarization reserve reduction in the bidirectionally 
and unidirectionally coupled cellular electrophysiology-force models without HCM-
induced myofilament remodeling elicited EADs similar to those shown previously 
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(Vandersickel et al., 2014; Zimik et al., 2015), which resulted in an elongated active force 
transient, as expected (Coppini et al., 2013). However, there needed to be a sufficient 
reduction in repolarization reserve for EADs to emerge (Vandersickel et al., 2014; Zimik 
et al., 2015). An example of unaffected APs (without EADs) when repolarization reserve 
reduction is insufficient (GKr 50% of baseline, GCaL 3.8 fold above baseline) in the 
bidirectionally (light blue) and unidirectionally (red) coupled models is shown in Figure 
5.2A, where transmembrane voltage (Vm) is plotted as a function of time for pacing at a 
CL of 2000 ms (0.5 Hz) and a SL of 1.90 µm. The corresponding active force traces, as a 
function of time (Figure 5.2C), were also unchanged. There were no differences in the APs 
or normalized active force traces between the bidirectionally and unidirectionally coupled 
models, despite a slight difference (32 µM vs 40 µM) in peak [Ca]Troponin (Figure 5.2B), 





Figure 5.2 Vm (row 1), [Ca]Troponin (row 2), and active force (row 3) are plotted over time 
for simulations incorporating HCM-induced ionic remodeling in the absence of 
myofilament remodeling for a pacing CL of 2000 ms, SL=1.90 µm, and GKr 50% of 
baseline. Columns 1-3 have progressively enhanced GCaL (3.8, 4.0, 4.2 fold above 
baseline), illustrating that the degree of repolarization reserve reduction affects the 
emergence of EADs and the frequency of their occurrence differently for simulations with 
the bidirectionally coupled model (with MEF; light blue) vs the unidirectionally coupled 
model (without feedback; red).  
 
An example of APs with EADs (sufficient reduction in repolarization reserve 
ensured by GCaL 4.0 fold vs 3.8 fold above baseline, other parameters identical to those in 
Figure 5.2A-C) in the bidirectionally coupled model (light blue) is shown in Figures 5.2D 
and 5.3A, and the corresponding prolonged active force trace in Figures 5.2F and 5.3B. If 
MEF is removed, the resulting unidirectionally coupled model does not exhibit EADs or 
prolongation of the active force trace, despite the significant reduction in repolarization 
reserve. In the bidirectionally coupled model, Troponin C binds free intracellular Ca2+ and 
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decreases the pool of free Ca2+ ions available in the cytoplasm ([Ca]i) as shown in Figure 
5.3C. During the early AP, the feedback via the [Ca]Troponin term (Equation 5.1) shown in 
Figures 5.2E and 5.3D in the bidirectionally coupled model, resulted in smaller peak [Ca]i 
than that in the unidirectionally coupled model. This smaller [Ca]i in the bidirectionally 
coupled model causes the sodium-calcium exchanger current (INaCa) in Figure 5.3E to be 
larger while functioning in its reverse mode (since it is a function of the Ca2+ gradient 
across the membrane), allowing more Ca2+ ions into the cell without dramatically 
increasing [Ca]i (since many of these Ca2+ ions then bind to Troponin C). As the AP 
progresses, the remaining Ca2+ ions in the cytoplasm are available to be extruded from the 
cell via INaCa during its forward mode or via the sarcolemmal calcium pump (IpCa) shown 
in Figure 5.3F, or pumped into the sarcoplasmic reticulum (SR; Figure 5.3G) via the 
sarcoplasmic reticulum Ca2+-ATPase (Iup; Figure 5.3H). However, since INaCa is a function 
of the Ca2+ gradient across the membrane and since [Ca]i is smaller due to buffering by 
Troponin C in the bidirectionally coupled model, less Ca2+ ions are extruded from the cell 
via INaCa thereby leaving more to be pumped into the SR via Iup. Larger [Ca]SR in 
simulations with the bidirectionally coupled model increases the opening rate and 
decreases the closing rate of the ryanodine receptor (RyR), resulting in larger Ca2+ release 
from the SR (Irel; Figure 5.3I) and increased Ca2+ in the subspace ([Ca]ss; Figure 5.3J). If 
[Ca]ss is sufficiently large (as it is for the bidirectionally but not unidirectionally coupled 
model), spontaneous calcium-induced calcium release (CICR) occurs. This further 
increases [Ca]ss, which then via increased diffusion (Ixfer; Figure3K), dramatically increases 
[Ca]i during early repolarization resulting in increased INaCa in forward mode. If the inward 
current from INaCa in forward mode delays repolarization long enough (as it does with the 
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bidirectionally coupled model), ICaL, as shown in Figure 5.3L, is able to recover from 
inactivation and increase enough to overcome the outward current through the rapid and 
slow delayed rectifier channels (IKr and IKs; Figures 5.3M-N), causing an EAD to form. 
This exemplifies how MEF can elicit EADs in bidirectionally coupled electrophysiology-
force cell models under conditions of significant repolarization reserve, when EADs are 
not elicited in comparable simulations with the unidirectionally coupled model. Therefore, 
MEF diminishes the degree of repolarization reserve reduction necessary for EADs to 
emerge in simulations with the bidirectionally coupled model compared to those with the 






Figure 5.3 Vm (A), active force (B), [Ca]i, (C), [Ca]Troponin (D), INaCa (E), IpCa (F), [Ca]SR 
(G), Iup (H), Irel (I), [Ca]SS (J), Ixfer (K), ICaL (L), IKr (M), and IKs (N) are plotted over time 
for simulations incorporating HCM-induced ionic remodeling in the absence of 
myofilament remodeling for a pacing CL of 2000 ms, SL=1.90 µm, GKr 50% of baseline, 
and GCaL 4.0 fold above baseline, highlighting the mechanism underlying the effects of 
MEF on EAD emergence and frequency by comparing the bidirectionally coupled model 
(with MEF; light blue) to the unidirectionally coupled model (without MEF; red).  
 
When repolarization reserve is reduced further (GCaL increased to 4.2 fold above 
baseline), both the bidirectionally and unidirectionally coupled models exhibit at least one 
AP with an EAD (Figure 5.2G) and one corresponding force trace that is of increased 
duration (Figure 5.2I). However, due to the difference in buffering of Ca2+ as a result of 
MEF (Figure 5.2H), the frequency of EAD occurrence is increased in the bidirectionally 
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coupled model relative to the unidirectionally coupled one (2 APs with an EAD vs 1). After 
an EAD occurs in beat one, there is an excess of Ca2+ ions in the cytoplasm, due to Ca2+ 
release from the SR and from reactivated ICaL, for simulations with both the bidirectionally 
and unidirectionally coupled models. In the bidirectionally coupled model, some of those 
Ca2+ ions bind to Troponin C, reducing [Ca]i during the 2nd repolarization relative to that 
in the unidirectionally coupled model. The remaining free Ca2+ ions in the cytoplasm are 
then pumped into the SR by Iup, or extruded from the cell via INaCa, and IpCa. However, the 
decreased [Ca]i reduces forward mode INaCa and enhances the amount of Ca2+ stored in the 
SR for bidirectionally vs unidirectionally coupled models. If sufficiently large (as it is in 
this example for the bidirectionally but not unidirectionally coupled simulations), this 
[Ca]SR load is enough to cause increased Irel and elevated [Ca]ss in the second beat 
triggering spontaneous CICR and an EAD, thus increasing the frequency of EAD 
occurrence in bidirectionally vs unidirectionally coupled simulations due to MEF.  
 
5.3.2 Faster Pacing Enhances Effects of MEF on EAD Emergence and 
Frequency 
The stability diagrams of GKr and GCaL in Figure 5.4A-C illustrate that EADs arise 
when HCM-induced repolarization reserve is sufficiently reduced (smaller GKr and larger 
GCaL) in the absence of HCM-induced myofilament remodeling, most prominently at faster 
pacing rates; the light blue line divides simulations with the bidirectionally coupled model 
that elicited no EADs (on the left) from those that had at least one EAD (on the right) for 
CLs of 4000 ms (Figure 5.4A), 2000 ms (Figure 5.4B) and 1000 ms (Figure 5.4C), with 
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SL=1.90 µm. The red lines denote the same division for simulation results with the 
unidirectionally coupled model. 
 
 
Figure 5.4 Stability diagrams of GKr and GCaL for simulations with the bidirectionally (light 
blue) and unidirectionally (red) coupled model incorporating HCM-induced ionic 
remodeling in the absence of myofilament remodeling for SL=1.90 µm at pacing CL=4000 
ms (A) 2000 ms (B) and 1000 ms (C). The light blue (and red) line divides results of 
simulations with the bidirectionally coupled (unidirectionally coupled) model that elicited 
no EADs (on the left) from those that had at least one EAD (on the right). Simulations 
represented by the points on the lines all contained at least one EAD, except for 3 
simulations at CL=4000 ms, with GCaL=5*baseline and GKr = 80, 90, 100% of baseline, 
respectively. Frequency of EAD occurrence is plotted in (D)-(F) for simulations at three 
representative points labeled a, b, and c in the corresponding stability diagrams in (A)-(C). 
Simulations at a, b, and c have GKr=20, 50 and 80% of baseline and the following GCaL 
values: 3.95, 4.60 and 5.00 times larger than baseline at CL=4000 ms; 3.75, 4.20 and 4.65 
times larger at CL=2000 ms; and 3.30, 3.70, 3.95 times larger at CL=1000 ms.  
 
Faster pacing enhanced the effects of MEF on the emergence of EADs, which is 
evidenced by the progressive separation of the red and light blue lines in Figure 5.4A-C. 
For pacing at CL=4000 ms, the degree of repolarization reserve reduction necessary to 
elicit EADs was similar for the bidirectionally and unidirectionally coupled models as 
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shown in Figure 5.4A (minimal separation between lines); the minimum amount of 
repolarization reserve reduction necessary to elicit EADs was decreased on average by 
1.0% for simulations with vs without MEF. At CL=2000 ms and CL=1000 ms, this effect 
was amplified; the minimum amount of repolarization reserve reduction necessary to elicit 
EADs was decreased on average by 4.6% at CL=2000 ms and 15.1% at CL=1000 ms for 
simulations with vs without MEF. This enhanced effect of MEF on the emergence of EADs 
with faster pacing was due to the progressively elevated [Ca]i during the early AP, which 
occurred due to a buildup of diastolic [Ca]i as a result of the progressively shorter time 
between beats needed for the Iup, INaCa, and IpCa to restore [Ca]i to normal. In the 
bidirectionally coupled model, this elevation in [Ca]i was lower than it was in the 
unidirectionally coupled model because some of the excess Ca2+ ions were able to bind to 
Troponin C instead of remaining unbound in the cytosol. Since Troponin C did not become 
saturated with Ca2+ even at the fastest pacing rates, the difference between [Ca]i in 
simulations with the unidirectionally vs bidirectionally coupled models was progressively 
enhanced as pacing rates were increased (CLs decreased). This difference in [Ca]i, as 
described in Results section 3.1 (via altered INaCa behavior, greater [Ca]SR, enhanced Irel, 
enlarged [Ca]ss, and CICR), reduced the degree of repolarization reserve reduction 
necessary for EADs to emerge in simulations with the bidirectionally coupled model. Since 
the difference in [Ca]i between the unidirectionally and bidirectionally coupled models 
progressively increased with increased pacing rate, the difference in the degree of 




Faster pacing also heightened the effects of MEF on the frequency of EAD 
occurrence. In Figure 5.4D-F, the frequency of EAD occurrence (defined in Methods 2.4) 
was plotted at three representative points labeled a, b, and c in the corresponding stability 
diagrams in Figure 5.4A-C. At these points, MEF increased the frequency of EAD 
occurrence in bidirectionally vs unidirectionally coupled simulations on average by 8.7% 
for CL=4000 ms (Figure 5.4D), 64.7% for CL=2000 ms, and 86.7% at CL=1000 ms. This 
progressive increase in EAD frequency with faster pacing, is due to progressively elevated 
[Ca]i during the early AP resulting in increasingly elevated [Ca]SR in the bidirectionally vs 
unidirectionally coupled models, as described in the preceding paragraph. Via the 
mechanism described in Results section 3.1, this progressive elevation in [Ca]SR in the 
subsequent beat progressively increased the probability of spontaneous CICR and thus the 
frequency of EAD occurrence. 
 
5.3.3 Longer Sarcomere Length Diminishes MEF Effects on EAD Emergence 
and Frequency 
Stability diagrams of GKr and GCaL, similar to those in Figure 5.4, illustrate how SL 
affects the degree of HCM-induced repolarization reserve reduction necessary for EAD 
emergence in simulations with the bidirectionally coupled electrophysiology-force 
myocyte model in the absence of HCM-induced myofilament remodeling for pacing at 
CL=2000 ms (Figure 5.5A) and CL=1000 ms (Figure 5.5B) for SL=1.70 µm (dark blue), 
1.90 µm (light blue), and 2.40 µm (green). Since pacing at CL=4000 ms elicited little 
difference in the amount of repolarization reserve necessary for EAD formation or the 
frequency of EADs between the bidirectional and unidirectional models, we did not 
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evaluate the effects of SL for pacing at CL=4000 ms.  Pacing at CL=2000 ms, contracted 
myocytes (SL=1.70 µm) compared to those at resting length (SL=1.90 µm) required on 
average 2.4% less reduction in repolarization reserve for EAD emergence (dark blue line 
left shifted relative to light blue line). Stretched myocytes (SL=2.40 µm) required on 
average 2.1% more repolarization reserve reduction for EAD emergence compared to those 
at resting length (green line right shifted relative to light blue line). These examples show 
that shorter SLs enhance EAD formation. By definition, increasingly shorter SLs have a 
progressively decreased fraction of single-overlap thin filament opposing the thick 
filament. Since this portion of the thin filament has a higher binding affinity to calcium, a 
progressively smaller fraction of it causes Ca2+ to dissociate increasingly faster from 
Troponin C during early repolarization in simulations with shorter vs longer SLs. This 
reduction of Ca2+ buffering by Troponin C enhances [Ca]i during early repolarization 
resulting in enhanced forward mode INaCa. Since forward mode INaCa produces an inward 
current, increasingly larger INaCa for shorter SLs resulted in longer delays in AP 
repolarization. These increased delays provided ICaL with progressively longer times to 
recover from voltage-gated inactivation and to self-amplify sufficiently to become greater 
than the sum of outward currents (including IKr). Since ICaL is a function of GCaL, cases with 
diminished GCaL will require more time for self-amplification. Similarly, enhanced GKr will 
result in larger outward currents requiring that ICaL be larger in order to overcome them, 
and thus requiring a longer period of delayed repolarization to allow greater self-
amplification of ICaL. Since shorter SLs at CL=2000 ms result in increased delays in AP 
repolarization, EADs are elicited in simulations with increasingly large repolarization 
reserve (progressively larger GKr and smaller GCaL). However, SL does not affect the degree 
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of repolarization reserve reduction necessary for EAD emergence at CL=1000 ms (Figure 




Figure 5.5 Stability diagrams of GKr and GCaL, similar to those in Figure 5.4, for 
simulations with the bidirectionally coupled electrophysiology-force myocyte model 
without myofilament remodeling for pacing at CL=2000 ms (A) and CL=1000 ms (B) for 
SL=1.70 µm (dark blue), 1.90 µm (light blue), and 2.40 µm (green). Frequency of EAD 
occurrence is plotted in (C)-(D) for simulations at three representative points labeled a, b, 
and c in the corresponding stability diagrams in (A)-(B). Simulations at a, b, and c have 
GKr=20, 50 and 80% of baseline and the following GCaL values: 3.55, 4.05 and 4.55 times 
larger than baseline at CL=2000 ms, and 2.75, 3.10 and 3.40 times larger at CL=1000 ms.  
 
Longer SLs also diminished the effect of MEF on the frequency of EAD 
occurrence. In Figure 5.5C-D, the frequency of EAD occurrence was plotted for both 
models at three representative points labeled a, b, and c in the corresponding stability 
diagram in Figure 5.5A-B. The frequency of EAD occurrence at these points illustrates 
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longer SLs result in fewer EADs. At SL=2.40 µm there are 52.7% less EADs than at 
SL=1.90 µm and 76.0% less than at SL=1.70 µm for CL=2000 ms (Figure 5.5C). For 
CL=1000 ms (Figure 5.5D), SL=2.40 µm had 0.7% less EADs than SL=1.90 µm and 4.7% 
less than SL=1.70 µm. Similarly, SL=1.90 µm resulted in 23.3% less EADs than SL=1.70 
µm at CL=2000 ms, and 5.3% less than SL=1.70 µm at CL=1000 ms. This decrease in the 
frequency of EAD occurrence for longer SLs is due to the enhanced binding affinity of 
Troponin C for Ca2+. Via the mechanisms described in the preceding paragraph, this results 
in shorter delays in AP repolarization at longer SLs. When an equal degree of repolarization 
reserve reduction is incorporated in simulations, the cases with shorter delays in AP 
repolarization (due to diminished INaCa in forward mode) are less likely to have ICaL recover 
from inactivation and are thus less likely to exhibit EADs. Therefore, longer SLs are 
associated with a diminished frequency of EAD occurrence. 
 
5.3.4 Increased Severity of HCM-Induced Myofilament Remodeling Alters 
Effects of MEF on EAD Emergence and Frequency 
Stability diagrams of GKr and GCaL, similar to those in Figures 5.3 and 5.4, illustrate 
how the severity of HCM-induced myofilament remodeling affects the degree of HCM-
induced repolarization reserve reduction necessary for EAD emergence in simulations with 
the bidirectionally coupled electrophysiology-force myocyte model. Figure 5.6 presents 
results regarding HCM-induced myofilament remodeling of parameters perm50 (Figure 
5.6A), koffH (Figure 5.6B), and kon (Figure 5.6C) for pacing at CL=2000 ms and SL=1.90 
µm. Simulations for the bidirectionally coupled model with both HCM-induced ionic and 
myofilament remodeling with CL=4000 ms and 1000 ms, and for CL=2000 ms with 
SL=1.70 and 2.40 µm are not shown since the effects of myofilament remodeling severity 
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on MEF effects on EAD formation are similar to those shown in Figure 5.6. A 15% increase 
in perm50, a 15% increase in koffH, or a 15% decrease in kon, decreases the degree of 
repolarization reserve reduction required for EAD emergence (left shifted lines in Figures 
5.5A-C respectively) on average by 3.0%, 1.0%, and 1.4% respectively compared to no 
remodeling. The reverse is true for a 15% decrease in perm50, a 15% decrease in koffH, or a 
15% increase in kon; the degree of repolarization reserve reduction required for EAD 
emergence is increased on average by 1.2%, 1.2%, and 1.4% respectively compared to no 
remodeling. By definition, increasing perm50 decreases nearest-neighbor cooperativity, 
resulting in decreased binding affinity of Troponin C on nearby RUs to Ca2+, thus 
decreasing RU-based thin filament activation. By definition, increasing koffH (and 
decreasing kon) increases the unbinding rate (decreases the binding rate) of Ca to Troponin 
C, also resulting in decreased binding affinity of Troponin C to Ca2+, thus decreasing Ca-
based thin filament activation. These examples show that diminishing TroponinC-Ca2+ 
binding affinity via HCM-induced remodeling increases the likelihood for EAD formation 
and results in EADs in simulations under conditions of greater repolarization reserve, via 
the same mechanism described in Results section 3.3. Therefore, diminishing TroponinC-





Figure 5.6 Stability diagrams of GKr and GCaL, similar to those in Figures 5.3 and 5.4, for 
simulations with the bidirectionally coupled electrophysiology-force myocyte model with 
HCM myofilament remodeling in parameters perm50 (A), koffH (B), and kon (C) for pacing 
at CL=2000 ms and SL=1.90 µm. Frequency of EAD occurrence is plotted in (D)-(F) for 
simulations at three representative points labeled a, b, and c in the corresponding stability 
diagrams in (A)-(C). Simulations at a, b, and c have GKr=20, 50 and 80% of baseline and 
GCaL values 3.50, 4.05, and 4.50 times larger than baseline.  
 
HCM-induced myofilament remodeling also affected the frequency of EAD 
occurrence. In Figure 5.6 D-F, the frequency of EAD occurrence was plotted for 
simulations with the bidirectionally coupled electrophysiology-force myocyte model at 
three representative points labeled a, b, and c in the corresponding stability diagram in 
Figure 5.6A-C. The graphs illustrate that HCM-induced myofilament remodeling that 
decrease the binding affinity of Troponin C to Ca2+ (increased perm50, increased koffH, 
decreased kon) results in a larger number of EADs than in cases without remodeling. 
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Myofilament remodeling that increases TroponinC-Ca2+ binding affinity results in fewer 
EADs. Simulations with myofilament remodeling that decrease binding affinity (15% 
increase in perm50, 15% increase in koffH, and a 15% decrease in kon) have an average of 
25.3%, 13.3%, and 16.7% more EADs than respective simulations without myofilament 
remodeling at CL=2000 ms. Conversely, simulations with myofilament remodeling that 
increase binding affinity (15% decrease in perm50, 15% decrease in koffH, and a 15% 
increase in kon) have an average of 44.0%, 14.0% and 24.0% less EADs than respective 
simulations without myofilament remodeling at the same pacing rate. 
 
5.4 Discussion 
The present study examines whether myofilament protein dynamics mechanisms in 
HCM affect the incidence of EAD formation, which have been implicated as the primary 
mechanism underlying many arrhythmias associated with HCM. The goal of our study was 
to utilize the capability of mechanistic computer simulations to investigate whether 
myofilament protein dynamics mechanisms modulate EAD formation for varying degrees 
of reduced repolarization reserve in HCM, and to uncover how these mechanisms are 
affected by pacing rate, sarcomere length, and the severity of HCM-induced myofilament 
remodeling. Using bidirectionally and unidirectionally coupled human electrophysiology-
force ventricular myocyte models, we showed that MEF on calcium dynamics in the 
bidirectionally coupled model, via Troponin C buffering of cytoplasmic Ca2+, was the 
myofilament protein dynamics mechanism underlying EADs. We showed that 
incorporating MEF diminished the degree of repolarization reserve reduction necessary for 
EADs to emerge and increased the frequency of EAD occurrence, especially at faster 
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pacing rates. We also found that longer sarcomere lengths and enhanced thin filament 
activation diminished the effects of MEF on EADs. Together these findings demonstrate 
that myofilament protein dynamics mechanisms plays an important role in EAD formation 
and suggest that targeting MEF may be an alternative treatment approach for prevention of 
arrhythmia and thus SCD in HCM patients. 
 
5.4.1 Modulation of EAD Incidence Occurs via MEF   
SCD and arrhythmias have been shown to occur in patients with HCM, an inherited 
sarcomeric mutation-based disease (Coppini et al., 2013; Coppini et al., 2014; Maron et 
al., 2000). In addition, HCM patients with more than one sarcomeric mutation have a 
higher risk of SCD and a worse phenotype, independent of other risk factors (Van Driest 
et al., 2004). An important mechanism underlying many lethal arrhythmias found in HCM 
patients is EADs (Weiss et al., 2010; Yan et al., 2001), which also occur in patients with 
HCM (Coppini et al., 2013). In this HCM EAD study, the sarcomeric proteins cardiac 
myosin binding protein C and myosin heavy chain were mutated and evidence of altered 
[Ca]i transient kinetics was found. Furthermore, additional sarcomere mutations such as 
Troponin I (Messer et al., 2007), T (Miller et al., 2001), and C (Olivotto et al., 2015) and 
tropomyosin (Olivotto et al., 2015) have been found in HCM, all of which are sarcomeric 
proteins integral to Ca2+-Troponin C binding (Tardiff et al., 2015). Taken together, the 
results from these previous studies suggest that MEF, via altered Troponin C-Ca2+ 
buffering, is a likely mechanism by which sarcomeric mutations can modulate the 
incidence of EADs. Our results presented here provide proof that sarcomeric mutations, 
via altered Troponin C buffering of cytosolic Ca2+ (resulting from MEF), can indeed alter 
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the degree of repolarization reserve reduction necessary for EADs to emerge and the 
frequency of EAD occurrence. 
 
5.4.2 Effects of Altered Ca2+ Sensitivity on EADs and Arrhythmia in HCM 
Ca2+ sensitivity is defined as the amount of Ca2+ necessary to produce half maximal 
force. When Ca2+ sensitivity is increased, less Ca2+ is required to produce half maximal 
force. Several studies have shown that increased Ca2+ sensitivity is associated with 
increased arrhythmogenicity (Baudenbacher et al., 2008; Huke and Knollmann, 2010). One 
animal study showed that the myosin inhibitor blebbistatin (which decreases Ca2+ 
sensitivity) reduced arrhythmia propensity in  mice who had been hypersensitized to Ca2+ 
due to troponin mutations or Ca2+ sensitizing agents (Baudenbacher et al., 2008). Another 
showed that transgenic mice with different troponin T and I mutations had an increased 
incidence of premature ventricular complexes when injected with isoproterenol and an 
increased occurrence of ventricular tachycardia (Baudenbacher et al., 2008). However, 
none of these studies were conducted on human tissue or models and none incorporated 
the ionic remodeling changes that have been shown to occur in human HCM (Coppini et 
al., 2013). Neither did they investigate the myofilament protein dynamics mechanisms 
linking increased Ca2+ sensitivity to EADs or arrhythmia. 
Human studies of HCM have shown that Ca2+ sensitivity is increased and that 
ventricular arrhythmias and SCD occur in HCM patients (Tardiff et al., 2015). However, 
ventricular arrhythmias and SCD also occur in dilated cardiomyopathy (DCM), which is 
characterized by a decrease in Ca2+ sensitivity (Sen-Chowdhry and McKenna, 2012). 
Therefore, to understand how altered Ca2+ sensitivity may potentially promote 
arrhythmogenicity in these sarcomeric mutation-based cardiac diseases, studies 
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investigating the effects of Ca2+ sensitivity on the mechanisms underlying arrhythmia are 
needed.  
This study investigated the effects of increased Ca2+ sensitivity on EADs in a 
bidirectionally coupled human HCM myocyte model. Our results show that sarcomeric 
mutations, which disrupt the regulation of the thin filament (decreased perm50, decreased 
koffH, increased kon) in a way that has a downstream effect of increasing Ca2+ sensitivity, 
increase the degree of repolarization reserve reduction necessary for EADs to emerge and 
decreases the frequency of EAD occurrence. Combined with the observations from the 
previous studies, this suggests that the enhanced arrhythmogenicity seen in HCM is not 
due to altered Ca2+ sensitivity, but rather due to HCM-induced ionic remodeling as 
suggested by Coppini et al (Coppini et al., 2013) or from secondary effects of myofilament 
remodeling at the tissue level, such as hypertrophy and fibrosis (Chan et al., 2014; Nucifora 
et al., 2015).  
 
5.4.3 Limitations 
A limitation of this study is that we do not incorporate sympathetic and 
parasympathetic stimulation, which is present during the cardiac cycle and could influence 
calcium cycling. Additionally, the conclusions of this study are in the context of a single 
myocyte; full understanding of the effects of myofilament dynamics on triggered activity 





MEF, via Troponin C buffering of cytoplasmic Ca2+, was the myofilament protein 
dynamics mechanism modulating EAD formation in a bidirectionally coupled human 
electrophysiology-force myocyte model of HCM. Our results demonstrate that accounting 
for MEF on calcium dynamics diminished the degree of repolarization reserve reduction 
necessary for EADs to emerge and increased the frequency of EAD occurrence, especially 
at faster pacing rates. Longer sarcomere lengths and enhanced thin filament activation 
diminished the effects of MEF on EADs. These findings demonstrate that myofilament 
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Atrial fibrillation (AF) is the most common type of human cardiac arrhythmia 
which, due to its association with increased morbidity and mortality and its rising 
prevalence, has become a global health care concern (Ball et al., 2013; Chugh et al., 2014; 
Lip et al., 2012). Unfortunately, current therapies do not directly target the underlying 
mechanisms of AF (Fabritz et al., 2016; Hanley et al., 2016), due in part to an incomplete 
understanding of atrial arrhythmogenesis. Therefore, to enhance prevention and treatment 
of AF, our understanding of its underlying disease mechanisms needs to be expanded. 
Action potential duration (APD) alternans (APD-ALT) is defined as beat-to-beat 
oscillations in APD. In human chronic AF (cAF), APD-ALT has been found to occur at 
heart rates of 120-200 beats per minute (bpm) (Narayan et al., 2002). Consequently, APD-
ALT has been proposed as an important clinical marker for AF risk since its onset is at 
slower rates in cAF patients than in healthy subjects and since it always precedes AF 
initiation (Narayan et al., 2002). In addition, an increased propensity for APD-ALT in cAF 
has been shown to increase arrhythmia complexity and persistence (Chang and Trayanova, 
2016). These findings indicate that APD-ALT occurring at slower rates (120-200 bpm) 
may be an important therapeutic target in AF patients. 
APD-ALT at these clinically-relevant slower rates has been found to be driven by 
calcium transient alternans (CA-ALT) (Chang et al., 2014). Specifically, altered ryanodine 
receptor (RyR) kinetics and down regulation of L-type calcium (Ca2+) current have been 
identified as the components of the cAF-associated ionic remodeling that drive APD-ALT 
formation at the clinically-relevant slow heart rates (Chang et al., 2014). While the ionic 
mechanisms of APD-ALT formation in human cAF have been elucidated, little is known 
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about the effects of myofilament protein dynamics on APD-ALT, particularly at the 
clinically-relevant slower rates. Understanding whether myofilament protein dynamics 
modulates APD-ALT is important because it has been previously shown to alter Ca2+-
driven voltage alternans in failing human ventricular myocytes (Zile and Trayanova, 2016). 
Myofilament remodeling has been documented in myocytes from cAF patients, including 
alterations in sarcomeric protein expression and phosphorylation, active and passive 
tension, myofilament calcium sensitivity, and crossbridge (XB) cycling rates (Belus et al., 
2010; Eiras et al., 2006; El-Armouche et al., 2006). Finally, mechanical stretch, common 
in cAF (Thanigaimani et al., 2017), has been shown to increase the susceptibility of atrial 
myocytes to APD-ALT and enhance their spatial discordance (Tsai et al., 2011). Therefore, 
our goal in this study was to utilize the capability of mechanistic computer simulations to 
investigate whether remodeling in myofilament protein dynamics in human cAF alters 
APD-ALT at the clinically-relevant slow heart rates, and how the established relationships 





6.2.1 Human Atrial Electromechanical Myocyte Model 
To achieve the goals of this study, a human atrial electromechanical myocyte 
model was developed that combined the human atrial ionic model by Chang et al (Chang 
et al., 2014), shown in Figure 6.1A, and the human myofilament dynamics model by Zile 
et al (Zile and Trayanova, 2016; Zile and Trayanova, 2017) shown in Figure 6.1B. This 
human atrial ionic model was chosen due to its ability to generate APD-ALT at slower 
clinically-relevant pacing rates (Chang et al., 2014; Chang and Trayanova, 2016), 
consistent with findings in human cAF (Narayan et al., 2011). We modeled both right 
atrial (RA) and left atrial (LA) myocytes as done in Chang et al (Chang et al., 2014).  
The Zile et al myofilament dynamics model, an extension of the Rice et al model 
(Rice et al., 2008) to the human myocyte from the original rabbit model, describes the 
activation of the thin filament by intracellular calcium binding to the regulatory site on 
Troponin C as well as thin filament binding to thick filament crossbridges (XBs) using a 
6-state Markov model. Since the Zile et al myofilament model was developed to match 
human ventricular myocyte force data, here we made additional adjustments to match 





Figure 6.1 Bidirectionally Coupled Electromechanical Model of the Atrial Myocyte. 
The human atrial ionic model by Chang et al (A) and the human myofilament model by 
Zile et al modified to match human atrial force data (B) are coupled (C) by incorporating 




The ionic and myofilament models were bidirectionally coupled by having thin 
filament activation depend on the amount of free calcium in the cytosol ([Ca2+]i) and by 
incorporating mechanoelectric feedback (MEF) on calcium dynamics. Specifically, the 
[Ca2+]i transient derived from the ionic model was used to drive thin filament activation in 
the myofilament model. Further, similarly to our previously developed approach (Zile and 
Trayanova, 2016; Zile and Trayanova, 2017), we incorporated MEF on calcium dynamics 
by replacing the existing state variable formulation for regulatory troponin C buffering of 
intracellular calcium ([Ca2+]Troponin) in the ionic model with the myofilament protein 
dynamics-dependent formulation from the myofilament model. Coupling the ionic and 
myofilament models bidirectionally with a myofilament protein dynamics-dependent 
representation of [Ca2+]Troponin was necessary here because such coupling has been shown 
to be crucial for accurately reproducing contractile experimental data in myocyte 
simulations (Ji et al., 2015).  
Using this bidirectionally coupled electromechanical model, we adjusted 
myofilament parameters to match normal human atrial force data. To do this, we solved a 
minimization problem similar to the approach by de Oliveira et al (de Oliveira et al., 2013), 
where the myofilament parameters (par) were adjusted to minimize the error between 
simulated and experimental values of total twitch time (TT), time to peak tension (TPT), 
and time to 50% relaxation of force (Trel50%), using the following equation: 
 
𝐸𝑟𝑟𝑜𝑟(𝑝𝑎𝑟) =  |𝑇𝑇𝑠𝑖𝑚(𝑝𝑎𝑟) −  𝑇𝑇𝑒𝑥𝑝| + |𝑇𝑃𝑇𝑠𝑖𝑚(𝑝𝑎𝑟) − 𝑇𝑃𝑇𝑒𝑥𝑝|






where TTexp, TPTexp, and Trel50%, exp are the values (listed in Table 6.1, row 4) of each force 
characteristic averaged across three sets of experimental data (Bisping et al., 2007; 
Goetzenich et al., 2009; Maier et al., 2000). In these experiments, human RA myocytes 
(with SL of 2.4 µm and at temperature of 37 °F) were isometrically paced at 1Hz (1000 ms 
pacing cycle length) until steady state was reached. The variables TTsim(par), TPTsim(par), 
and Trel50%, sim(par) were computed from our simulations with human RA myocytes, each 
run with a unique set of 11 adjusted myofilament parameters (par) as listed in the following 
notation: 
 
𝑝𝑎𝑟 = [𝑘𝑛𝑝, 𝑘𝑝𝑛, 𝑔𝑎𝑝𝑝, 𝑓𝑎𝑝𝑝, ℎ𝑓, ℎ𝑏, 𝑔𝑥𝑏, 𝑝𝑒𝑟𝑚50, 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓𝐻 , 𝑘𝑜𝑓𝑓𝐿] 
 
For each unique set of par, the myofilament parameters above were each assigned a value 
between 25% and 400% (in increments of 25%) of their control value from our earlier 
electromechanical model of the normal human ventricular myocytes (Zile and Trayanova, 
2016). The set of adjusted myofilament parameters which resulted in the smallest error 
(0.2093) between simulation results and experimental data (the set to be referred to as 
parmin), as calculated from Equation 6.1, was used in this study. In parmin, the majority of 
myofilament parameters ended up not being altered, with the exception of knp (25% of 
control), kpn (150% of control), and gapp (200% of control). These adjusted myofilament 
parameter values are listed in Table 6.2. The force characteristic values (TTsim(parmin), 
TPTsim(parmin), and Trel50%, sim(parmin)) from simulations with this normal human RA 
myocyte model are shown in row 6 of Table 6.1 for comparison with experimental values. 
Since no experimental human LA force data could be found, we also used parmin for our 























Bisping et al N/A 89 ± 10 N/A 
Goetzenich  
et al 
N/A 95 ± 17 89 ± 14 
Maier et al 300 ± 24 91 ± 11 85 ± 7 
Average 300 92 87 
Range 276 – 324 78-112 75-103 
 
Simulation 301 77 91 
Table 6.1 Force Characteristics of Human Right Atrial Myocytes  
Force characteristics of human RA myocytes from experiments (Bisping et al., 2007; 
Goetzenich et al., 2009; Maier et al., 2000) and from simulations with our healthy human 
RA myocyte model using the myofilament parameter values parmin listed below in Table 
6.2. Force characteristics in row 4 are averaged from the available experimental data (in 
rows 1-3) and appear in Equation 6.1 as TTexp, TPTexp, and Trel50%,exp, respectively. TT = 
total twitch time, TPT = time to peak tension, Trel50%  = time to 50% relaxation of force. 
 
6.2.2 Incorporating cAF-Induced Remodeling 
Ionic remodeling in cAF resulting in the development of APD-ALT at clinically-
relevant slow rates as well as arrhythmogenesis was incorporated in LA and RA myocytes 
as described previously (Chang et al., 2014; Chang and Trayanova, 2016). Specifically, 
Chang et al decreased gNa by 10%, decreased gCaL by 50%, increased IbarNCX by 40%, 
increased ryanodine receptor Ca2+-dependent activation rate (koCa) 3-fold, decreased RyR 
Ca2+-dependent inactivation rate (kiCa) by 50%, increased sarcoplasmic reticulum (SR) 
Ca2+ leak by 25%, and increased gKs and gK1 each 2-fold compared to normal in both the 
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LA and RA myocytes. Chang et al also added a late component to the sodium current (INaL) 
in the LA and RA myocytes.  Finally, Chang et al decreased gKur by 45% and 55% and gto 
by 45% and 80% compared to normal in LA and RA myocytes, respectively.  
Myofilament remodeling representing abnormal force generation and myofilament 
Ca2+ sensitivity found in cAF was incorporated next. Active tension generation and 
relaxation rates have been shown to be slower and maximum active and passive force 
generation to be decreased in cAF myofibrils, suggesting that XB cycling rates are 
depressed (Belus et al., 2010; Eiras et al., 2006). In addition, myofilament Ca2+ sensitivity 
in human cAF myofibrils, as compared to normal, was found to be either significantly 
increased (Belus et al., 2010) or unchanged (Eiras et al., 2006). Furthermore, research has 
found alterations in sarcomeric protein expression and phosphorylation levels (Belus et al., 
2010; Cazorla et al., 2006; Eiras et al., 2006; El-Armouche et al., 2006), suggesting that 
myofilament Ca2+ sensitivity is increased (Belus et al., 2010; Cazorla et al., 2006).  
To incorporate decreased force generation rates and enhanced Ca2+ sensitivity in 
our atrial myofilament model, we increased thin filament activation and reduced XB 
cycling rates. We increased thin filament activation by increasing 2 parameters (kon, kn_p) 
and decreasing 4 parameters (perm50, koffL, koffH, kp_n). The parameters knpT and kpnT are 
nonlinear transition rates that are functions of these 6 parameters and represent calcium 
based activation of the thin filament, which is shown in Fig. 1 as the transition of the thin 
filament from the NXB state (XB formation is inhibited) to the PXB state (weakly bound XB 
formation is possible). The parameter perm50 is the half activation constant for the shift of 
a thin filament regulatory unit (RU) from NXB to PXB, koffH (koffL) is the rate constant for 
Ca2+ unbinding from the high (low) affinity binding site of Troponin C, and kon is the rate 
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constant for Ca2+ binding to Troponin C. The parameters kn_p and kp_n are constant scaling 
factors of the knpT and kpnT transition rates. We reduced XB cycling rates by increasing 2 
parameters (gapp, hb) and decreasing another three (fapp, hf, gxb). The rates fapp and gapp 
regulate the transition of the thin filament from the PXB state to the strongly bound XB 
state, where the myosin head has not yet rotated and thus not induced strain in the neck 
region (XBPreR). The parameters hf and hb are transition rates between the XBPreR and 
XBPostR states (thin filament is strongly bound to a XB, which has a rotated myosin head 
and has induced distortion). The parameter gxb represents the ATP consuming transition 
rate from XBPostR to PXB. Since cAF-induced changes in mechanical properties (described 
in the preceding paragraph) do not directly translate to changes in myofilament model 
parameters, and due to the progressive nature of remodeling in cAF (Narayan et al., 2011), 
we explored cAF–induced remodeling of these  myofilament model parameters within the 
range of 100% to 300% of their control values (increments of 25%) for kon, kn_p, gapp, and 
hb, and within the range of 100% to 20% of their control values (increments of 10%) for 



























kn_p 152.5 s-1 
gapp 186 s-1 










koffL 250 s-1 
koffH 25 s-1 
kp_n 24 s-1 
fapp 4800 s-1 
hf 10 s-1 
gxb 30 s-1 
Table 6.2 Healthy and cAF Values for Myofilament Model Parameters. 
Normal (N) and chronic atrial fibrillation (cAF) values of myofilament model parameters 
in the human LA and RA myocyte models. Myofilament parameters in parmin are bolded 
in column 2. 
 
6.2.3 Alternans Protocol  
To induce APD-ALT in our RA and LA cAF atrial myocyte models, we used a 
pacing protocol similar to that used in a clinical study by Narayan et al (Narayan et al., 
2011) and in alternans computational studies (Chang et al., 2014; Chang and Trayanova, 
2016). We first isometrically paced the myocyte model at a CL of 750 ms (80 bpm) until 
steady state was reached. Then, we paced it for 74 beats at each successive CL starting at 
500 ms and descending, in 50 ms increments, to 300 ms. The analysis of simulation results 
focused particularly on assessing alternans levels from beats paced at a CL of 400 ms (150 
bpm), since Narayan et al (Narayan et al., 2011) observed that that was the average 
alternans onset CL in cAF patients. 
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To determine how the severity of cAF-induced myofilament remodeling alters 
APD-ALT, we incorporated different amounts of cAF-induced myofilament remodeling in 
our simulations. One of the 11 myofilament parameters (perm50, koffL, koffH, kp_n, fapp, hf, 
gxb, kon, kn_p, gapp, and hb) was assigned a non-control value (as described in the previous 
section) for a given simulation. To determine how SL modifies the effects of MEF on APD-
ALT formation, we ran each of these simulations for a SL value between 1.7 and 2.3 µm 
(in increments of 0.1 µm). These SLs were chosen because they represent the SL range that 
occurs during a normal cardiac cycle (Trayanova and Rice, 2011a). 
. 
 
6.2.4 Analysis of Alternans 
APD was defined as the time from maximal upstroke velocity to 90% repolarization 
of transmembrane voltage (Vm) from peak amplitude (Hayashi et al., 2003; Kim et al., 
1997). APD alternans normalized magnitude (APD-ANM) was calculated (Chang et al., 
2014; Chang and Trayanova, 2016; Narayan et al., 2011) as the mean magnitude of change 
in APD over the last 10 pairs of beats (11 total beats) at a given pacing CL divided by the 
mean APD over the final 10 beats, using the equation below: 
 
𝐴𝑃𝐷 − 𝐴𝑁𝑀 =  
∑ ( |𝐴𝑃𝐷𝑖 − 𝐴𝑃𝐷𝑖+1| )
 𝑏𝑒𝑎𝑡 #73
 𝑖=𝑏𝑒𝑎𝑡 #63 10⁄
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝐴𝑃𝐷 𝑓𝑜𝑟 𝑏𝑒𝑎𝑡𝑠 64−74




[Ca2+]i and [Ca2+]Troponin (CA-ALT and CaT-ALT respectively) were quantified in the same 
manner as APD-ALT with the change in each variable defined as the difference in 
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amplitude between beats. Alternans normalized magnitude (ANM) > 5% was the threshold 
for ANM to be considered significant. 
 
6.3 Results 
6.3.1 The Effect of Bidirectionally Coupling a Myofilament Model to the Ionic 
Model: MEF Alters Normal Membrane Kinetics 
Coupling our model of the normal myocyte bidirectionally (i.e. representing the 
effect of MEF on the ionic component of the model) altered the membrane kinetics in the 
ionic component of our electrotechnical model compared to the uncoupled ionic model of 
the normal myocyte. This is shown in Figure 6.2 for the action potential, [Ca2+]i, and 
[Ca2+]Troponin. APD90 and [Ca2+]i transient behavior are slightly different in our 
electromechanical RA model compared to the RA ionic model (APD90 300 vs 284 ms; 
[Ca2+]i,diastolic 0.1997 vs 0.2066 µM; [Ca2+]i transient amplitude 0.3631 vs 0.2570 µM). 
Importantly, the APD90, [Ca2+]i,diastolic, and [Ca2+]i transient amplitude derived from our 
electromechanical model are in better agreement with currently available experimental 
human RA data (range 255-344 ms; 0.1197 µM; 0.3449 µM) (Christ et al., 2008; Voigt et 





Figure 6.2 Vm (A), [Ca2+]i (B), and [Ca2+]Troponin (C) plotted over time for our 
electromechanical model (blue) and the uncoupled ionic model of the normal RA myocyte 
(Chang et al., 2014; Chang and Trayanova, 2016). 
 
6.3.2 The Effect of Coupling a Myofilament Model to the cAF Ionic Model: 
Presence of MEF Diminishes APD-ANM 
Since MEF changed the [Ca]i transient in our bidirectionally coupled 
electromechanical models compared to the uncoupled ionic models of the normal RA and 
LA myocytes (Chang et al., 2014; Chang and Trayanova, 2016), we investigated whether 
MEF could also modulate alternans in our cAF RA and LA electromechanical myocyte 
models. Incorporating only cAF-induced ionic remodeling (without myofilament 
remodeling, i.e. the myofilament model was that of a normal RA or LA myocyte) in our 
RA and LA electromechanical myocyte models resulted in sub-threshold alternans (ANM 
<5%) in APD, [Ca2+]i, and [Ca2+]Troponin for the last 62 beats of the 74 beat train. An 
example is shown by the blue traces in Figure 6.3A-C, where Vm, [Ca2+]i, and [Ca2+]Troponin 
are plotted for the RA myocyte as functions of time for the final two beats. APD-ANM, 
CA-ALT normalized magnitude (CA-ANM), and CaT-ALT normalized magnitude (CaT-
ANM) values are 0.03%, 0.02%, and 0.04% respectively. Although ANM was below 
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threshold for the final 62 beats, there were significant, though progressively diminishing, 
alternans for the first 12 beats of the 74 beat train (not shown). This is in contrast to results 
from our uncoupled ionic model, which demonstrated that ANM were maintained above 
threshold for the duration of the 74 beats. An example is shown by the red traces in Figure 
6.3A-C for Vm, [Ca2+]i, and [Ca2+]Troponin (ANM 16%, 75%, 99%, respectively). The 
dampening effect of MEF on alternans is owed to the difference in how the models 
represent Troponin C buffering of free cytosolic Ca2+. The uncoupled ionic model uses an 
equation that does not incorporate cooperativity (Michaelis-Menton formulation) unlike 
our electromechanical model, which uses a formulation that does incorporate key 
cooperativity mechanisms. The cooperativity mechanisms include the ability of strongly 
bound XBs to increase the binding affinity of Ca2+ to Troponin C on nearby RUs. 
Therefore, Ca2+-Troponin C affinity is enhanced when the amplitude of the [Ca]i transient 
is greater, resulting in more cytosolic Ca2+ ions binding to Troponin C during a long 
compared to a short beat. Since Ca2+ ions are removed from the cytosol when they bind to 
Troponin C, as the beat number progresses within the train of 74 beats, there is a 





Figure 6.3 Vm (A), [Ca2+]i (B), and [Ca2+]Troponin (C) plotted over time for simulations with 
our electromechanical RA myocyte model with only cAF-induced ionic remodeling 
incorporated (blue traces) and the uncoupled cAF RA ionic model (red traces). The final 
two beats (of the 74 total beats) isometrically paced at a CL of 400 ms and a SL of 1.9 µm 
are shown for each model.  
 
6.3.3 Increased cAF-Induced Myofilament Remodeling Predominantly 
Increases APD-ANM 
Incorporating both cAF-induced ionic and myofilament remodeling in our human 
RA and LA electromechanical myocyte models resulted, predominantly, in APD-ANM 
increases (Figure 6.4). Specifically, bifurcations in APD as functions of myofilament 
parameters occurred as the level of thin filament remodeling increased following changes 
in kon, koffH, and perm50 in RA and LA myocyte models (Figure 6.4, top). The increase 
in thin filament activation caused a transition from stable APD to beat-to-beat APD 
oscillations. In RA and LA models, significant APD-ANM (Figure 6.4, bottom) occurred 
for cAF-induced remodeling of kon>200% (RA) or kon>250% (LA); koffH< 40% (RA) 
or koffH< 30% (LA); and 30%<perm50< 60% (both LA and RA) of control values. cAF-
induced remodeling of other myofilament parameters that increased thin filament 
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activation (knp, kpn, koffL) or those which led to a reduced rate of XB cycling (gapp, hb, 
fapp, hf, and gxb) did not alter APD-ANM (not shown).  
 
 
Figure 6.4 Bifurcation diagrams for APD (row 1) and sensitivity of APD-ANM (row 2) as 
functions of cAF-induced myofilament remodeling in simulations with our RA (blue) and 
LA (green) electromechanical models with cAF-induced ionic remodeling and a SL of 1.9 
µm. To incorporate cAF-induced increased thin filament activation, each unique simulation 
has a cAF-remodeled value of kon (column 1), koffH (column 2), or perm50 (column 3) 
ranging from normal (100% of control) to diseased (300% of control for kon; 20% of control 
for koffH and perm50). The pink dashed line in row 2 indicates the division between sub-
threshold ANM and significant ANM (> 5%). 
 
An increase in thin filament activation enhanced the binding affinity of Troponin C 
for Ca2+, thus increasing the fraction of Troponin C with bound Ca2+ during both long and 
short beats. However, as more Ca2+ binds to Troponin C, the fraction of Troponin C with 
bound Ca2+ reached saturation (i.e., a value of one) during the long beat. As a result, the 
fraction of Troponin C bound to Ca2+ during the short beat increased relative to that during 
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the long, causing a concomitant relative increase in the fraction of strongly bound XBs. 
Due to the cooperativity between strongly bound XBs and Ca2+-Troponin C binding 
affinity on nearby RUs, this caused a further increase in Ca2+-Troponin C affinity. As a 
result, [Ca]Troponin increased, and the peak magnitude of [Ca]i decreased during the short 
beat relative to the long, increasing CA-ANM. Therefore, as cAF-induced thin filament 
activation increased, APD-ANM also became larger. An example of this is shown in Figure 
6.5, where we compare Vm, [Ca]i, the fraction of strongly bound XBs, and [Ca]Troponin for 
simulations with different amounts of cAF-induced remodeling of thin filament activation.  
When cAF-induced remodeling of thin filament activation is increased from 150% to 225% 
of control, increases are found in APD-ANM (to 9.4% from 0.03%), CA-ANM (to 43% 
from 0.02%), CaT-ANM (to 74% from 0.03%), and the maximum percent of XBs in a 






Figure 6.5 Vm (A), [Ca2+]i (B), the percentage of regulatory units with strongly bound XBs 
(C), and [Ca2+]Troponin (D), plotted over time for our RA electromechanical myocyte models 
with cAF-induced ionic remodeling. The final two beats (of the 74 total beats) isometrically 
paced at a SL of 1.9 µm with cAF-induced myofilament remodeling with a value of kon = 
150% (blue lines), at a SL of 1.9 µm with kon = 225% (red lines), or at a SL of 2.3 µm with 
kon = 150% (green line) are shown. The percentage of regulatory units with strongly bound 
XBs is calculated as the sum of RUs in the XBPreR and XBPostR states divided by the total 
number of RUs.  
 
Sub-threshold APD-ANM (Figure 6.4, bottom) occurred for RA and LA models 
with values of perm50<=30%. In these cases, the fraction of Troponin C with bound Ca2+ 
became close to saturation during both short and long beats. Therefore, the binding affinity 
of Troponin C to Ca2+ was reduced in the short beat relative to that in the long one, causing 
the difference in the amount of Ca2+ buffered by Troponin C between successive beats to 
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progressively diminish. Since Ca2+ ions are removed from the cytosol when they bind to 
Troponin C, this leads to progressive dampening of CA-ALT, and thus of APD-ALT. 
 
6.3.4 Longer SLs Predominantly Increase APD-ANM 
Finally, we investigated the effect of SL on APD-ANM, since stretch is common 
in cAF (Thanigaimani et al., 2017) and has been shown to increase the susceptibility of 
atrial myocytes to APD-ALT (Tsai et al., 2011). The results of the simulations revealed 
that longer SLs predominantly increase APD-ANM for both RA and LA electromechanical 
myocyte models, as seen in Figure 6.6 for simulations with cAF-induced myofilament 
remodeling represented by kon (column 1), koffH (column 2), and perm50 (column 3). An 
increase in SL increases the thin filament single overlap region, resulting in greater thin 
filament activation and enhanced binding affinity of Troponin C to Ca2+. As described in 
Section 6.3.3, when binding affinity is heightened, the fraction of Troponin C with bound 
Ca2+ reaches saturation during only the long beats, resulting in larger APD-ANM. An 
example of this is shown in Figure 6.5 for simulations at two different SLs. When SL is 
increased from 1.9 µm to 2.3 µm, increases are found in APD-ANM (to 15% from 0.03%), 
CA-ANM (to 94% from 0.02%), CaT-ANM (to 124% from 0.03%), and the maximum 
percent of XBs in a strongly bound state (to 42% from 1.8% during the first beat; to 16% 
from 1.8% during the second beat). For simulations with SLs above 2.1 µm and with the 
greatest cAF-induced myofilament remodeling (kon >275% for RA only, koffH<30% and 
perm50< 50% for both RA and LA), the binding affinity of Troponin C to Ca2+ was largest. 
When the binding affinity is greatest, the fraction of Troponin C with bound Ca2+ reaches 




Figure 6.6 Sensitivity of APD-ANM to SL in simulations with our RA (row 1) and LA 
(row 2) electromechanical myocyte models with cAF-induced ionic remodeling and 
varying degrees of cAF-induced myofilament remodeling. cAF-induced myofilament 
remodeling was incorporated as in Figure 6.4. Each white dot represents a unique 
simulation in which the model was isometrically paced at a specific SL ranging from 1.7 
to 2.3 µm in increments of 0.1 µm. Colors represent APD-ANM. Contour lines were drawn 
at APD-ANM of 5, 10, 15, and 20%. 
 
6.4 Discussion 
An increased propensity for APD-ALT has been shown to render the human atria 
vulnerable to ectopy-induced arrhythmia and to increase arrhythmia complexity and its 
persistence in computational models of human cAF (Chang and Trayanova, 2016). These 
simulation results are consistent with studies demonstrating that atrial alternans is linked 
to disease progression in AF patients (Narayan et al., 2011), and is associated with 
enhanced AF susceptibility following myocardial infarction in clinical studies (Kettlewell 
et al., 2013; Miyauchi et al., 2003) and atrial tachycardia in animal models (Jousset et al., 
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2012; Monigatti-Tenkorang et al., 2014). Recent studies have also examined the cellular 
mechanism underling the occurrence of APD-ALT at clinically-relevant slow pacing rates, 
120-200 bpm (Chang et al., 2014; Chang and Trayanova, 2016). Although researchers have 
examined the ionic mechanisms underlying APD-ALT, the effects of myofilament protein 
dynamics on APD-ALT had not been elucidated. Here, we investigated whether 
myofilament protein dynamics mechanisms modulate APD-ALT formation in cAF at 
clinically-relevant pacing rates. By comparing our human electromechanical atrial 
myocyte model to the human ionic atrial model, we showed that MEF has a dampening 
effect on APD-ANM. These results are consistent with our previous simulation study, 
where we showed that MEF diminished calcium and voltage alternans, driven by heart 
failure-induced downregulation of the SR Ca2+ uptake current, in simulations of failing 
human ventricular myocytes (Zile and Trayanova, 2016). Since APD-ALT has been 
advocated as a clinical marker for AF risk and has been suggested as a new therapeutic 
target in cAF patients (Chang et al., 2014; Chang and Trayanova, 2016; Narayan et al., 
2002), our results propose that targeting myofilament protein dynamics may offer an 
alternative approach for prevention of arrhythmia in cAF patients.  
We also examined how APD-ALT is affected by cAF-induced myofilament 
remodeling. Previous studies have suggested that myofilament Ca2+ sensitivity, the amount 
of Ca2+ necessary to produce half maximal force, is increased in AF (Belus et al., 2010; 
Eiras et al., 2006), although the degree to which it is increased and whether it promotes 
arrhythmogenicity in AF has not been elucidated. Therefore, in this study we investigated 
how varying degrees of increased thin filament activation, which enhances Ca2+ sensitivity, 
altered the formation of APD-ALT. Our results show that increasing thin filament 
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activation and thus Ca2+ sensitivity, via MEF, predominantly enhanced APD-ANM. Since 
APD-ALT has been identified as a dynamic arrhythmogenic substrate underlying human 
AF and since APD-ANM is larger in cAF patients than in paroxysmal AF ones (Narayan 
et al., 2002), our observations suggest that myofilament remodeling may occur in cAF 
patients but not in paroxysmal ones. This is supported by Belus et al (Belus et al., 2010) 
who found that myofilament Ca2+ sensitivity was increased in human cAF (long-standing 
persistent AF), while Eiras et al (Eiras et al., 2006) found that there was no significant 
difference in myocytes from healthy and persistent AF patients. Therefore, enhanced Ca2+ 
sensitivity may be responsible for the enhanced arrhythmogenicity found in cAF patients 
compared to persistent AF patients. However, organ-scale simulations will be necessary to 
verify this hypothesis. Furthermore, our results suggest that therapies decreasing the 
disease-enhanced thin filament activation could reduce APD-ANM, thus potentially 
reducing the propensity for arrhythmia in AF patients.  
Acute and chronic stretch are known to cause abnormal atrial remodeling and to 
increase vulnerability to AF (Thanigaimani et al., 2017). Acute atrial stretch causes 
transient electrophysiological changes such as conduction slowing and altered atrial 
refractoriness in animal (Ravelli and Allessie, 1997; Sideris et al., 1994; Solti et al., 1989) 
and human (Elvan et al., 2013; Ravelli et al., 2011) studies. Chronic atrial stretch has been 
implicated in structural atrial remodeling and persistent conduction slowing in both animal 
(Takeuchi et al., 2006) and human (Morton et al., 2003) studies. Although investigators 
have examined some of the proposed mechanisms by which atrial stretch can lead to AF 
(Franz and Bode, 2003), such as stretch-activated ion channels (Kim, 1992; Tavi et al., 
1996), few studies have examined the effects of atrial stretch on APD-ALT. One study by 
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Tsai et al (Tsai et al., 2011) found that mechanical stretch in an HL-1 atrial myocyte 
monolayer led to increased susceptibility to CA-ALT and APD-ALT, due to slower 
calcium reuptake kinetics via decreased expression of SR adenosine triphosphatase 2. 
However, only rapid field pacing could induce APD-ALT in this study. This is in contrast 
to the clinical observations (Narayan et al., 2011) showing that APD-ALT occurs in cAF 
patients at slower rates, thus these finding may be more relevant to paroxysmal AF patients 
(Kalifa and Yamazaki, 2011). Therefore, we investigated how stretched sarcomeres 
affected the formation of APD-ALT at clinically-relevant pacing rates in human cAF. Our 
findings at slower clinically-relevant rates of 150 bpm (400 ms CL), similar to those from 
Tsai et al (Tsai et al., 2011) at faster pacing rates of 240-360 bpm (250 ms – 167 ms CL), 
showed that simulated myocytes with longer SLs resulted in enhanced APD-ANM due to 
larger CA-ANM, suggesting that atrial stretch is an important modulator of APD-ALT. 
Therefore, therapies designed to reduce the mechanical stretch commonly found in cAF 
may reduce the propensity for arrhythmia in these patients. 
 
6.5 Conclusions 
Our results demonstrate that enhanced thin filament activation was the key feature 
of cAF-induced myofilament remodeling that predominantly enhanced CA-ANM and thus 
APD-ANM in simulated human cAF myocytes. Furthermore, longer SLs chiefly 
heightened APD-ANM at slower clinically-relevant rates of 400 ms (150 bpm). Together 
our findings demonstrate that myofilament dynamics mechanisms play an important role 














In this thesis, we have demonstrated that cardiac disease induced-remodeling of 
myofilament parameters and sarcomere length, due to the presence of MEF, altered the 
formation of alternans in human HF and cAF, and EADs in human HCM. Furthermore, we 
showed that CA-ALT, induced by decreased Iup, was the link between APV-ALT and 
FORCE-ALT in human HF. Unfortunately, we were only able to simulate human atrial and 
ventricular myocytes; we did not have the opportunity to explore the effects of MEF, 
deranged myofilament dynamics, or stretch on the initiation of arrhythmia in myocardial 
tissue. However, computational modeling is uniquely placed to address this gap of 
knowledge. To explore the exciting future directions listed below, the first step would be 
to build bidirectionally coupled multiscale models of the human tissue and ventricles 
incorporating HF-induced and HCM-induced ionic and myofilament remodeling, and a 
bidirectionally coupled multiscale model of the human tissue and atria incorporating cAF-
induced ionic and myofilament remodeling. Building these models would allow one to 
investigate the following: 
 
Future Directions from Study 1:  
• At the Tissue Level: Investigate if spatially discordant force alternans arises at fast 
pacing rates in human HF.  If it does arise, characterize discordant force alternans 
sensitivity to pacing rate and heterogeneity of electrical and mechanical properties.  
• At the Organ Scale: Investigate whether the summation of force alternans in the 
ventricles results in clinically observed pressure alternans. Characterize if and how 
pressure alternans enhance prediction of arrhythmia propensity. 
Future Directions from Study 2:   
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• At the Tissue and Organ Levels: Investigate the effects of myofilament dynamics 
on triggered activity (the manifestation of EADs at the tissue/organ level) and 
arrhythmogenesis. Determine how heterogeneity of myofilament remodeling 
across the tissue/organ effects arrhythmogenesis.  
Future Directions from Study 3:  
• At the Tissue Level: Investigate if spatially discordant APD alternans arises in 
human cAF and how it is modulated by MEF.   
• At the Organ Scale: Investigate how myofilament dynamics affects the 
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